

1 **Lipidomics for diagnosis and prognosis of pulmonary hypertension**

2 Natalie Bordag^{1,2,3,15}, Bence Miklos Nagy², Elmar Zügner⁴, Helga Ludwig⁵, Vasile Foris^{2,6}, Chandran
3 Nagaraj^{2,15}, Valentina Biasin^{2,7}, Ulrich Bodenhofer⁵, Christoph Magnes⁴, Bradley A. Maron⁸, Silvia
4 Ulrich⁹, Tobias J. Lange^{10,11}, Konrad Hötzenecker¹², Thomas Pieber^{3,13,15}, Horst Olschewski^{2,6,15*},
5 Andrea Olschewski^{2,14,15}

6

7 **Affiliations**

8 ¹Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.

9 ²Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.

10 ³CBmed GmbH, Center for Biomarker Research in Medicine, Graz, Austria.

11 ⁴Institute for Biomedical Research and Technologies (HEALTH), Joanneum Research
12 Forschungsgesellschaft m.b.H, Graz, Austria.

13 ⁵School of Informatics, Communications, and Media, University of Applied Sciences Upper Austria,
14 Hagenberg, Austria.

15 ⁶Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz,
16 Austria.

17 ⁷Division of Physiology, Otto Loewi Research Centre, Medical University of Graz, Graz, Austria.

18 ⁸University of Maryland School of Medicine, Baltimore, MD and The University of Maryland-Institute
19 for Health Computing, Bethesda, MD, USA.

20 ⁹Clinic of Pulmonology, University and University Hospital of Zurich, Zürich, Switzerland.

21 ¹⁰Department of Internal Medicine II, Pulmonology and Critical Care, Kreisklinik Bad Reichenhall,
22 Bad Reichenhall, Germany.

23 ¹¹Faculty of Medicine, University of Regensburg, Regensburg, Germany.

24 ¹²Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

25 ¹³Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of
26 Graz, Graz Austria.

27 ¹⁴Experimental Anaesthesiology, Department of Anaesthesiology and Intensive Care Medicine,
28 Medical University of Graz, Graz, Austria.

29 ¹⁵BioMedTech, Graz, Austria.

30

31 *to whom correspondence should be addressed:

32 Prof. Horst Olschewski, Horst.Olschewski@medunigraz.at

33 **Abstract**

34 **Background**

35 Pulmonary hypertension (PH) poses a significant health threat with high morbidity and
36 mortality, necessitating improved diagnostic tools for enhanced management. Current biomarkers for
37 PH lack functionality and comprehensive diagnostic and prognostic capabilities. Therefore, there is a
38 critical need to develop biomarkers that address these gaps in PH diagnostics and prognosis.

39 **Methods**

40 To address this need, we employed a comprehensive metabolomics analysis in 233 blood based
41 samples coupled with machine learning analysis. For functional insights, human pulmonary arteries
42 (PA) of idiopathic pulmonary arterial hypertension (PAH) lungs were investigated and the effect of
43 extrinsic FFAs on human PA endothelial and smooth muscle cells was tested *in vitro*.

44 **Results**

45 PA of idiopathic PAH lungs showed lipid accumulation and altered expression of lipid
46 homeostasis-related genes. In PA smooth muscle cells, extrinsic FFAs caused excessive proliferation
47 and endothelial barrier dysfunction in PA endothelial cells, both hallmarks of PAH.

48 In the training cohort of 74 PH patients, 30 disease controls without PH, and 65 healthy controls,
49 diagnostic and prognostic markers were identified and subsequently validated in an independent cohort.
50 Exploratory analysis showed a highly impacted metabolome in PH patients and machine learning
51 confirmed a high diagnostic potential. Fully explainable specific free fatty acid (FFA)/lipid-ratios were
52 derived, providing exceptional diagnostic accuracy with an area under the curve (AUC) of 0.89 in the
53 training and 0.90 in the validation cohort, outperforming machine learning results. These ratios were
54 also prognostic and complemented established clinical prognostic PAH scores (FPHR4p and
55 COMPERA2.0), significantly increasing their hazard ratios (HR) from 2.5 and 3.4 to 4.2 and 6.1,
56 respectively.

57 **Conclusion**

58 In conclusion, our research confirms the significance of lipidomic alterations in PH, introducing
59 innovative diagnostic and prognostic biomarkers. These findings may have the potential to reshape PH
60 management strategies.

61

62 **Keywords**

63 biomarker, prognosis, pulmonary hypertension, blood-based test, fatty acid to lipid ratio, lipidomics

64 **Abbreviations**

65 6MWD, six minute walking distance; ACh, acetylcholine; ADMA, asymmetric
66 dimethylarginine; AUC, area under the curve; BH, Benjamini–Hochberg; BMI, body mass index; BNP
67 or NT-proBNP, natriuretic peptide levels; CO, cardiac output; COPD, chronic obstructive pulmonary
68 disease; CI, cardiac index; CTEPH, chronic thromboembolic pulmonary hypertension; DC, diseased
69 control (non-PH); DLCOcVA, diffusing capacity for carbon monoxide per alveolar volume,
70 hemoglobin corrected; ECAR, extracellular acidification rate; ECIS, electrical cell-substrate impedance
71 sensor; EDTA, ethylenediaminetetraacetic acid; FEV1, forced expiratory volume/ 1 s; FVC, forced vital
72 capacity; FFA, free fatty acids; H&E, hematoxylin-eosin; HC, healthy control; HILIC, hydrophilic
73 interaction liquid chromatography; hPAEC, human pulmonary artery endothelial cells; hPASMC,
74 human pulmonary artery smooth muscle cells; HR, hazard ratio; HRMS, high resolution mass
75 spectrometry; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; iPCA,
76 independent principal component analysis; IVD, *in vitro* diagnostics; LPC, lysophosphatidylcholine;
77 LPE, lysophosphatidylethanolamine; LV, left ventricle; MAD, median absolute deviation; mPAP, mean
78 pulmonary arterial pressure; MS, mass spectrometry; OCR, oxygen consumption rate; OPLS-DA,
79 orthogonal projections to latent structures discriminant analysis; PA, pulmonary arteries; PAH,
80 pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge
81 pressure; PBS, phosphate-buffered saline; PC, phosphatidylcholine; PDGF, platelet-derived growth
82 factor; PH, pulmonary hypertension; PPP, pentose phosphate pathway; PVR, pulmonary vascular
83 resistance; QC, pooled from samples for quality control; RAP, right atrial pressure; RDW, red cell
84 distribution width; RF, random forest; RHC, right heart catheterization; ROC, receiver operator curve;
85 RT, room temperature (20 – 25 °C); SEM, standard error of mean; SM, sphingomyelin; SMA, smooth
86 muscle actin; SvO2, mixed venous oxygen saturation; TAG, triacylglyceride; TEER, transendothelial
87 electrical resistance; TLC, total lung capacity; VWF, von-Willebrand Factor; WHO FC, World Health
88 Organization functional class; WU, Wood unit; XGBoost, eXtreme Gradient Boosting;

89 Introduction

90 Pulmonary hypertension (PH) affects 1% of the world's population^{1,2} and thus represents a
91 significant global health problem. Even mild PH is a strong negative prognosticator in patients with left
92 heart disease³, lung disease⁴, and pulmonary arterial hypertension (PAH)^{5,6}.

93 In recent decades, global research efforts have led to targeted therapies for the rare pulmonary
94 vascular diseases PAH and chronic thromboembolic PH (CTEPH). Despite this, the estimated five-year
95 survival rate for newly diagnosed PAH patients has remained at only 61%^{7,8}.

96 Diagnosis of PH is challenging because measurement of pulmonary arterial pressure (PAP)
97 requires right heart catheterization (RHC), whereas non-invasive methods provide only reliable
98 estimates of PAP¹ or are not widely available⁹. Natriuretic peptide levels (BNP or NT-proBNP) are the
99 only recommended biomarkers for PH, but they are not specific for pulmonary hypertension. Therefore,
100 the development of new diagnostic tools for the detection of PH, risk stratification, and epidemiological
101 studies remains an important issue².

102 Fibroproliferative remodelling of distal pulmonary arterioles drives elevation in pulmonary
103 vascular resistance and pulmonary arterial pressure. This is associated with unique metabolic changes
104 as detected from the circulation¹⁰⁻¹⁵ as a reflection of the profound changes in the cells and matrix of
105 the right ventricle and pulmonary vessel walls¹⁶. Our hypothesis was that PH patients may present with
106 a characteristic metabolic profile that allows for detection of PH and risk stratification¹. We identified
107 lipidomic changes in the small pulmonary arteries (PA) of IPAH patients and a unique lipidomic profile
108 in a diverse PH cohort, allowing identification of PH among healthy and diseased controls, which was
109 confirmed in an independent validation cohort. In addition, we show that simple markers of this
110 lipidomic profile are significantly associated with survival and improve the accuracy of two established
111 prognostic PAH scores.

112 Results

113 Clinical and cardiopulmonary hemodynamic characteristics for the study cohorts

114 Our study included three classes of subjects: PH patients, healthy control subjects (HC) and
115 lung disease controls (DC) without PH, all of whom underwent blood-based high resolution mass
116 spectrometry (HRMS)-based metabolomics (see Fig. 1). PH patients had a mean PAP
117 (mPAP) ≥ 25 mmHg and were either 1) PAH, 2) PH due to left heart disease (LV), 3) PH due to lung
118 disease, or 4) CTEPH. All DC had mPAP < 25 mmHg with either metabolic syndrome, chronic
119 obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The distributions in sex and
120 body mass index (BMI) between PH and HC/DC were similar (see Fig. 1C). Age was in the same range,
121 although controls tended to be younger. Metabolites were not significantly correlated with age (see Fig.
122 S3).




Fig. 1. Study overview for all cohorts. (A) Schematic workflow of metabolomics measurement and computational analysis. Created with BioRender.com. (B) Schematic overview of group distribution of all included patients (n = 233) in training and validation cohorts. (C) Scatter plot of BMI vs. age (shape of symbols by sex) in the training cohort with distribution histograms per PH and per HC/DC showing comparable distributions of sex and BMI in PH and HC/DC, avoiding potential confounders by design.

123 The training cohort consisted of PH patients, DC and HC, all sampled in Graz, Austria. The
124 external validation cohort contained PH patients and HC from Zürich, Switzerland and Regensburg,
125 Germany. Patient characteristics are summarized in Table 1.

126

127 **Table 1: Patients' characteristics (medians \pm 95% confidence interval)**

	Training (n=169)			Validation (n=64)	
	HC (n=65)	DC (n=30)	PH (n=74)	HC (n=7)	PH (n=57)
Age, years	58.0 \pm 2.8	59.5 \pm 4.7	66.5 \pm 3.0	42.0 \pm 13.8	57.0 \pm 3.7
Female:male (ratio)	44:21 (2.1:1)	20:10 (2.0:1)	50:24 (2.1:1)	5:2 (2.5:1)	43:14 (3.1:1)
BMI (kg/m ²)	24.1 \pm 0.9	26.2 \pm 3.0	25.9 \pm 1.1	21.0 \pm 1.7	26.3 \pm 1.4
Diagnosis (since years)	-	8 \pm 1.8	1.0 \pm 1.2	-	5.5 \pm 1.7
<i>Pulmonary hemodynamics from RHC</i>					
mPAP (mmHg) mean pulmonary arterial pressure	-	-	42.0 \pm 2.5	-	50.0 \pm 3.9
PAWP (mmHg) pulmonary arterial wedge pressure	-	-	10.0 \pm 1.3	-	9.0 \pm 0.9
CO (L/min) cardiac output	-	-	4.3 \pm 0.4	-	4.2 \pm 0.4
CI (L/min/m ²) cardiac index	-	-	2.6 \pm 0.2	-	2.4 \pm 0.2
PVR (WU) pulmonary vascular resistance	-	-	7.1 \pm 1.0	-	9.1 \pm 1.7
RAP (mmHg) right atrial pressure	-	-	6.0 \pm 1.2	-	7.5 \pm 1.1
<i>Clinical data</i>					
6MWD (m) 6-min walk distance	-	454 \pm 41	330 \pm 34	-	390 \pm 31
WHO FC world health organisation functional class	-	2.0 \pm 0.2	3.0 \pm 0.2	-	2.0 \pm 0.2
FEV1 (% predicted) forced expiratory volume 1 s	-	51.5 \pm 9.9	75.0 \pm 5.6	-	82.2 \pm 3.0
FVC (% predicted) forced vital capacity	-	63.8 \pm 6.7	82.8 \pm 5.5	-	91.4 \pm 4.0
FEV1/FVC (% predicted)	-	56.3 \pm 8.5	74.4 \pm 3.0	-	75.7 \pm 2.1
TLC (% predicted) total lung capacity	-	103.0 \pm 10.8	94.0 \pm 3.9	-	96.5 \pm 3.5
DLCO cSB (% predicted) single-breath CO diffusing capacity, haemoglobin corrected	-	49.6 \pm 7.8	63.8 \pm 6.0	-	53.8 \pm 3.9
DLCO cVA (% predicted) diffusing capacity for CO alveolar volume, haemoglobin corrected	-	70.0 \pm 7.9	69.6 \pm 6.1	-	62.0 \pm 3.7
RDW (%) red cell distribution width	-	14.0 \pm 0.7	15.4 \pm 0.7	-	14.7 \pm 0.6
NT-proBNP (pg/mL)	-	98 \pm 39	869 \pm 806	-	751 \pm 475
Uric acid (mg/dL)	-	5.0 \pm 0.5	6.0 \pm 0.6	-	6.6 \pm 0.7
Creatinine (mg/dL)	-	0.80 \pm 0.09	1.02 \pm 0.12	-	1.00 \pm 0.23
Bilirubin total (mg/dL)	-	0.40 \pm 0.13	0.64 \pm 0.13	-	0.65 \pm 0.16

128 Identification of a characteristic lipidomics profile in pulmonary hypertension

129 The metabolome of patients was assessed with untargeted hydrophilic interaction liquid
130 chromatography (HILIC)-HRMS from serum, EDTA, and heparin plasma samples in four measurement
131 runs. As is typical with mass spectrometry (MS) based metabolomics methods, notable batch effects
132 occurred between runs as well as drift within the longer runs (see Fig. S2). Drift correction was
133 successfully performed (see Fig. S2) using quality control (QC) injections, which are a mix of equal
134 sample volumes repeatedly measured to monitor instrument stability.

135 In total, 164 known metabolites were of consistent analytical quality suitable for multivariate
136 and univariate exploratory analysis. Global metabolic changes were first examined using the
137 unsupervised multivariate independent principal component analysis (iPCA). The metabolomes of the
138 PH patients differed from the control groups (HC and DC), which was visible as a clear group separation
139 in the iPCA scores plot along the first component (x-axis, Fig. 2A). The observed metabolic difference
140 was strongly driven by an increase in specific free fatty acids (FFA) in PH patients (Fig. 2B). The
141 machine learning method orthogonal projections to latent structures discriminant analysis (OPLS-DA)
142 confirmed that the observed global metabolic differences between PH and HC/DC were significant
143 ($p < 0.001$, cross-validation and 1000 random permutations, Fig. 2C).




Fig. 2. PH is associated with a strong metabolic shift in the training cohort. (A) iPCA scores plot representing the metabolic profile of each subject as a dot. The proximity of the dots indicates the similarity of the subjects' metabolomes. Clear group separation by PH is visible along the first component. (B) Loadings plot corresponding to scores plot in (A). Each dot represents the contribution of the metabolite to the group separation observed in the scores plot. FFAs (yellow circles) strongly drive the group separation and are increased in PH patients. (C) OPLS-DA maximizes the group difference from PH to HC/DC and the resulting scores plot represents, as in A, the metabolome of each subject. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. The difference between the metabolome of PH and HC/DC was significant ($Q^2 > 50\%$, $p < 0.001$ from 1000 random permutation). (D) Volcano plot of univariate analysis showing significant ($p_{BH} < 0.05$, grey horizontal line) and strong (absolute contrast ratio > 0.25 , grey vertical lines) increase in FFAs (yellow triangles). For all methods A-D, 164 known metabolites from the training cohort samples ($n = 169$) were used (drift corrected, \log_{10} -transformed data). Colors as in B.

144 The univariate statistical analysis confirmed that FFAs were strongly and significantly
145 increased in PH as compared with HC/DC (Fig. 2D). The metabolites from routine clinical chemistry,
146 e.g. uric acid, were strongly correlated with their respective HILIC-HRMS metabolites (Fig. S3). Single

147 FFAs and lipids were not strongly correlated with any clinical parameter, suggesting that the detected
148 FFA changes may be independent from conventional clinical assessment.

149 **FFA/lipid-ratios diagnose pulmonary hypertension**

150 The potential of using our metabolites to predict PH was first investigated with the machine
151 learning method random forest (RF)^{17,18} and extreme gradient boosting (XGBoost)¹⁹. From the 164
152 metabolites, 11 were excluded from biomarker analysis because of low signal intensities and high noise
153 (see Supplementary Data 1). RF and XGBoost both achieved an area under the curve (AUC) of 0.82 in
154 the receiver operator curve (ROC) analysis in the validation set (Fig. 3A). The drift correction used here
155 allowed a joint exploratory statistical analysis, but drift correction is impossible in future routine clinical
156 diagnostics. Therefore, the diagnostic and prognostic performance was also tested without drift
157 correction. RF and XGBoost performance were almost identical without drift correction, indicating that
158 their nonlinear algorithms exhibit intrinsic drift-handling capabilities (Fig. 3A).

159 Other important model performance parameters such as specificity, sensitivity, and balanced
160 accuracy were comparable for RF and XGBoost irrespective of drift correction. For RF and XGBoost,
161 the average balanced accuracy was 72.2% and 72.7%, respectively, the specificity was 88.6% and
162 91.2%, respectively, and the sensitivity was 55.8% and 54.1%, respectively (Fig. 3C). The validation
163 cohort had only seven HC and no DC with a slightly different age and BMI distribution than the training
164 cohorts. To overcome this limitation, we tested an artificial data split into 70% training and 30%
165 validation sets with balanced distributions in age, BMI, sex and disease class (PH/DC/HC). The
166 performance of RF and XGBoost remained similar to the original split by center (Fig. S4).




Fig. 3. Diagnostic accuracy for PH in training and validation cohorts. (A) ROC plots of RF (green) and XGBoost (blue) trained with data from training cohort predicting class in validation cohort with either drift corrected, \log_{10} -transformed data (left, middle) or non-drift corrected \log_{10} -transformed data (right) based on 153 metabolites. **(B)** The ROC plots of the three best FFA/lipid-ratios for training and validation cohort with either drift corrected, \log_{10} -transformed data or \log_{10} -transformed data with no drift correction (insets). **(A-B)** Training cohort $n = 169$ (solid line), validation cohort $n = 64$ (dashed line), ribbons mark 95% confidence intervals. **(C)** Plot of model performance metrics sensitivity, specificity and balanced accuracy for RF, XGBoost, and the three best FFA/lipid-ratios when based on either training (circles) or validation (diamonds) cohorts only or all available data (squares). The performance of RF and XGBoost was comparable for all three metabolite subsets with and without drift correction. The performance of the three best FFA/lipid-ratios was consistently more stable and balanced than of RF or XGBoost.

167 Despite their diagnostic potential, both machine learning approaches are not suitable for routine
168 clinical diagnostics because they are labour intensive and not fully explainable. In addition, both
169 approaches showed notable decreases in AUC, sensitivity, specificity and balanced accuracy from the
170 training to the validation cohort. Therefore, we tested whether ratios formed from lipophilic metabolites
171 with strong effects of PH versus HC/DC, normalized to metabolites with no effects of PH vs. HC/DC,
172 could replace machine learning approaches to create an explainable, easy-to-measure marker. In PH,
173 many FFAs were strongly increased while many complex lipids were unchanged (Fig. 2D), offering the
174 option to achieve markers of PH that are easy to measure. Thus, characteristic FFAs were selected into
175 the numerator, based on their analytical performance in PH versus HC/DC and lipids with good
176 analytical performance and non-significance in PH vs. HC/DC were chosen for the denominator.

177 For the nominator, 11 FFA were considered: FFA C15:0 (pentadecylic acid), FFA C16:2
178 (palmitolinoleic acid), FFA C16:1 (palmitoleic acid), FFA C17:1 (heptadecenoic acid), FFA C17:0
179 (margaric acid), FFA C18:3 (α -linolenic acid, ALA, or γ -linolenic acid, GLA), FFA C18:2 (linoleic
180 acid, LA), FFA C18:1 (oleic acid), FFA C19:1 (nonadecenoic acid), FFA C20:5 (eicosapentanoic acid,
181 EPA) and FFA C20:1 (eicosenoic acid). Eight lipids, the best two from four common classes, were
182 considered for the denominator: lysophosphatidylcholine (LPC) 18:2, LPC 18:1, phosphatidylcholine
183 (PC 36:4, PC 38:6), sphingomyelin (SM 34:2, SM 36:2), lysophosphatidylethanolamine (LPE) 16:0,
184 and LPE 18:1. To stabilize the ratios, we also tested sums of up to six FFAs in the numerator and up to
185 four lipids in the denominator, limiting the maximum number of individual metabolites in a given ratio
186 to ten.

187 In total, about a quarter of a million FFA/lipid-ratios were evaluated for their diagnostic
188 performance in ROC analysis. Most FFA/lipid-ratios achieved moderate to high performance with
189 AUCs above 0.8 (Fig. S5A-I,K,L) irrespective of drift correction or split. There may be a concern that
190 combining multiple metabolites in a ratio increases technical error and impairs reproducibility.
191 However, in our cohort, the calculated technical variability according to the laws of error propagation
192 was <5% for most FFA/lipid-ratios and <10% for all others (Fig. S5J).

193 For simplicity, the top three ratios were selected, based on their AUC, sensitivity, and
194 specificity, and named RATIO1, RATIO2, and RATIO3 (Fig. S5M). These ratios had six metabolites
195 in common: numerator (FFA C20:1 + FFA C16:1 + FFA C15:0); denominator (PC 38:4 + PC 36:4 +
196 LPC 18:1). Compared to RATIO 1, the only difference of RATIO 2 and 3 was the addition of two more
197 FFA to the numerator sum (FFA 18:3 + FFA 17:0 and FFA 18:2 + FFA 17:0, Fig. 3B). The ROC curves
198 of RATIO1-3 overlapped well between training and validation cohort, irrespective of drift correction
199 (Fig. 3B). All other important performance parameters were also very similar between RATIO1-3
200 (Fig. 3C). As a general result, top ratios outperformed the machine learning models, irrespective of drift
201 correction or data split, especially in terms of sensitivity. The top three ratios' average balanced
202 accuracy was 85.5%, with 89.7% specificity and 81.4% sensitivity (Fig. 3C).

203 FFA/lipid-ratios massively reduced technical complexity compared to broad metabolomics runs
204 while achieving better diagnostic performance than machine learning approaches. The diagnostic
205 performance of the FFA/lipid-ratios was independent of drift correction, making them suitable for
206 stand-alone measurements. Accordingly, we assume that FFA/lipid-ratios are suitable for future routine
207 applications.

208 **Specific FFA/lipid-ratios predict survival**

209 The prognostic value of RATIO1 was compared with well-established prognostic PAH scores,
210 FPHR4P²⁰ (based on WHO FC, 6MWD, RAP, and CI) and COMPERA2.0^{1,21} (based on WHO FC,
211 6MWD, and NT-pro-BNP). Survival and hazard ratios (HR) were investigated for all our patients with
212 heart or lung disease and PH. For direct comparability of Kaplan-Meier survival curves and HRs, all
213 numeric values were categorized into low or high risk according to their optimal cut-off points (e.g. 57
214 years for age).

215 We analysed survival times since enrolment (= baseline) which were available for 129 PH and
216 21 DC (13 COPD, 8 ILD) patients. The COMPERA2.0 score was available for 122 PH and 11 DC
217 patients, and FPHR4p for 97 patients (93 PH and 4 DC). Survival times and both scores were available
218 for 91 PH patients. As expected, FPHR4p and COMPERA2.0 scores were significantly associated with
219 survival time (Fig. 4). RATIO1 was also significantly associated with survival (Fig. 4) with a similar
220 HR as COMPERA2.0 scores. When RATIO1 was combined with each of the scores (RATIO1 and
221 score equally weighted), the prognostic value of the respective score improved notably (Fig. 4). This
222 indicates that our simple metabolomic marker provided independent prognostic information and would
223 complement established prognostic scores.

224 As expected, established prognostic risk factors from the literature, higher WHO FC, lower
225 6MWD, and higher NT-proBNP were associated with poorer survival (Fig. S7). Next, we examined the
226 major potentially confounding factors age, sex and BMI. Age > 57 yr constituted a considerable risk
227 factor, while BMI > 26.8 kg/m² and male sex were not significant (Fig. S6). Results were similar in the
228 joint model for all three factors, suggesting that only age was a relevant confounder. Therefore, we
229 included only age as covariate to our HR analysis (Fig. 4A).




Fig. 4. RATIO1 predicts survival and improves prediction of established clinical scores. (A) Cox HR analysis for survival from baseline without age as confounder (left side) and with age (right side, age HR shown in grey). Whiskers marks the 95% confidence intervals and statistical significance is coded as: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. Combining RATIO1 with FPHR4P or COMPERA2.0 increased HR compared with either alone. (B, C, D) Kaplan–Meier curves of survival from baseline by (B) RATIO1, (C) FPHR4p, and (D) COMPERA2.0 alone and combined with RATIO1. All cut-offs defining high or low were optimized with maxstat. RATIO1 was based on \log_{10} -transformed data without drift correction. RATIO1 was combined scaled 0 to 1 with equal weighing with either each score. FPHR4p was inverted so that higher scores represent higher risk as in COMPERA2.0.

230 Overall, the HR results with age as covariate were similar to those without (Fig. 4A) and
 231 although age correction caused a decrease of all HR values, their respective prognostic impact remained
 232 significant.

233 Changes in lipid metabolism in pulmonary arteries of idiopathic PAH (IPAH) patients

234 We investigated small PA from IPAH patients, the prototype of PAH and healthy donor lungs
 235 from explanted lungs. Oil red O staining and co-staining with markers of endothelial and smooth muscle
 236 cells showed accumulation of lipids in several IPAH PA (Fig. 5A). The observed lipid deposition could
 237 be the result of increased fatty acid uptake, metabolic dysregulation, or increased lipid synthesis.
 238 Therefore, we performed laser-capture microdissection of small PA (< 500 μm) from IPAH patients
 239 and healthy donors and examined gene expression of transporters and enzymes related to lipid
 240 metabolism. Gene expression showed significant upregulation of several key genes involved in lipid
 241 uptake and metabolism in IPAH (Fig. 5B). Most striking was the significant upregulation of SLC27A5,
 242 GAPT1, AGAPT1, Lipin2 and DGAT1. DGAT1 plays a critical role in lipid droplet formation. Up-

243 regulation of the FFA transport protein SLC27A5 indicates increased uptake of FFAs from the
 244 circulation. GPAT, AGPAT, and lipin family enzymes promote triglyceride biosynthesis, incorporation
 245 of exogenous fatty acids into triacylglycerides (TAG) and phospholipids, as well as β -oxidation. The
 246 upregulation of these genes in the small PAs of IPAH patients might be caused by the increased
 247 circulating FFA levels or might be a manifestation of an underlying disease mechanism.




Fig. 5. Presence of lipids and expression of lipid-metabolism genes in IPAH pulmonary arteries. (A) Visualization of endothelium (von-Willebrand factor, VWF) and smooth muscle cell layer (smooth muscle actin, SMA) together with oil red staining in human IPAH lung serial sections (scale bar: 50 μ m). (B) Gene expression of lipid homeostasis-related enzymes in laser-capture microdissected human PA (n = 8-10 patients, respectively). Vertical lines represent means with standard error of mean (SEM). Asterisks mark Mann Whitney test p < 0.05. Cell organelles are adapted from Servier Medical Art (CC BY 2.0 DEED).

248 Next, we mimicked elevated circulating FFA levels by treating primary human pulmonary
 249 artery smooth muscle cells (hPASMC) and human pulmonary artery endothelial cells (hPAEC) from

250 healthy donors with a FFA cocktail. Bodipy fluorescence staining showed accumulation of fat in
251 hPASMCs and hPAECs (Fig. 6A). To better understand the functional effects of this, we performed in-
252 vitro studies with primary hPAEC and hPASMCs. In hPASMCs, the treatment with the FFA mixture
253 significantly promoted cell proliferation (Fig. 6B), and in hPAECs it significantly decreased
254 acetylcholine (ACh)-induced NO secretion, suggesting endothelial dysfunction (Fig. 6C).

255 We investigated the effect of the FFA mixture on endothelial barrier function by determining
256 the magnitude of thrombin-induced endothelial barrier dysfunction. Fig. 6D shows the typical response
257 of control endothelium to thrombin. When endothelial monolayers were pre-treated with FFA, they
258 exhibited a significantly pronounced decrease in transendothelial electrical resistance (TEER) and
259 delayed recovery of barrier function compared to control media (Fig. 6D). This suggests that FFA
260 treatment causes profound endothelial dysfunction. Finally, we examined FFA-induced metabolic
261 responses in hPASMCs and hPAECs by means of the Seahorse method and found significantly
262 decreased coupling efficiency in both cell types in response to FFA treatment (Fig. 6E, F). Moreover,
263 FFA exposure decreased non-mitochondrial respiration and ATP production in hPAEC and increased
264 proton leak in hPASMC. This suggests that FFA treatment changes the phenotype of hPASMCs and
265 hPAECs from healthy donors into an IPAH phenotype and that high levels of circulating FFAs may
266 cause pulmonary vascular dysfunction, representing either a primary cause or a novel vicious circle in
267 PH.

268




Fig. 6. Effects of FFA treatment on hPASMC and hPAEC. (A) Representative Bodipy fluorescence staining of hPASMC and hPAEC in the absence (Ctrl) or presence of extrinsic FFA (scale bar: 50 μ m). (B) Platelet-derived growth factor (PDGF)-BB induced proliferation of primary hPASMC measured with thymidine incorporation, in the absence (Ctrl) or presence of extrinsic FFA (n = 4). Changes are expressed as percentages compared with untreated controls (Ctrl). (C) ACh-induced NO production in primary hPAEC (n = 4). Changes are expressed as percentage compared with untreated controls (Ctrl). (D) TEER, as determined by electrical cell-substrate impedance sensor (ECIS), showed a significant decrease in hPAEC treated with FFA, suggesting endothelial leakage. Representative original curve (left panel) and changes expressed as percent change compared with controls (Ctrl) (n = 4). (E, F) Summarized data from hPASMC and hPAEC using the Seahorse XFe24 Extracellular Flux Analyzer. All measurements were performed on n = 25,000–50,000 cells/well and five wells per cell type. Each experimental group consisted of cell lines from two to three patients. All data were normalized to total protein per well before analysis (n = 9). Mann Whitney test * < 0.05, ** < 0.01, *** < 0.001. The boxes extend from the 25th to 75th percentile, the middle line denotes the median and the whiskers mark the minimum and maximum.

269 Discussion

270 The uptake and metabolism of long-chain fatty acids is critical for many physiological and
271 cellular processes, and cellular accumulation may cause numerous pathological and functional changes.
272 Previous investigations in PAH have shown severe metabolic changes of the right ventricle and elevated
273 *in vivo* myocardial triglyceride content^{10,22,23}. Our investigations add important information by showing
274 that small PA of IPAH patients are affected by lipid accumulation. Interestingly, we found increased
275 gene expression of enzymes causing fatty acid uptake and triglyceride biosynthesis in smooth muscle
276 cells of IPAH patients (Fig. 5C). This could be caused by the high FFA levels in the circulation,
277 however, it could also represent a change in the cell physiology that strongly contributes to the
278 development of PH.

279 For the first time, we have explored the effects of FFA exposure in primary human hPAECs
280 and hPASMCs. FFA exposure decreased NO secretion and impaired barrier function in hPAECs, and
281 caused increased proliferation in hPASMC. In addition, FFA exposure induced changes in non-
282 mitochondrial respiration and coupling efficiency in both cell types. This suggests that impaired lipid
283 handling in IPAH PAs might trigger the remodelling in PAH. This is in line with numerous studies
284 indicating that the expression of GAPAT1 / AGPAT1 / lipin-1 has important metabolic consequences²⁴⁻
285 ²⁷. Our data, taken in context with data from the literature, may suggest that in PH, the failing right
286 ventricle is no longer able to cope with FFA metabolism, leading to an increase in circulating FFA
287 levels, which negatively affects the pulmonary vessels. However, it is also possible that there are
288 primary changes in the lipid metabolism of the small PAs, leading to vascular dysfunction, subsequently
289 increasing right ventricular afterload, initiating a vicious circle that finally causes PH and right heart
290 failure.

291 Spanning over two decades, extensive basic, translational, and clinical analyses have supported
292 a causative link between metabolic reprogramming and PAH^{28,29}. Similar to the Warburg effect in
293 cancer, a shift from mitochondrial oxidation to glycolysis appears to occur in the right ventricle of PAH
294 patients^{22,23}. In this study, we show that the small PAs are affected by significant metabolic changes.
295 Taking cues from cancer, recent data demonstrate significant alterations in metabolic programs other
296 than glycolysis and glucose oxidation, including the pentose phosphate pathway (PPP), glutaminolysis,
297 lipolysis, fatty acid synthesis and oxidation and changes in the plasma proteome^{10-16,30-32}. However, it
298 remains unclear whether these changes originate in the overloaded right ventricle, in the primarily
299 affected pulmonary vessels, or elsewhere.

300 Although there has been tremendous progress in the understanding of PAH in recent decades,
301 there is still an unmet need for diagnostics and therapy. According to a recent literature review, the five-
302 year survival rate for newly diagnosed patients has not significantly improved despite a multitude of
303 new PAH medications⁸. This may be due to the fact that the metabolic mechanisms of the disease have

304 not been addressed in detail. To our knowledge, this study is the first to apply unsupervised, broad
305 metabolome analysis of PH patients of group 1 to 4. The generated specific FFA/lipid-ratios identified
306 patients with PH, independent of comorbidities. The same ratios provided prognostic information,
307 complementing existing clinical prognostic scores. The diagnostic and prognostic results were validated
308 in an independent international cohort and this was confirmed by a balanced split group approach. Of
309 note, our *in vitro* mechanistic studies suggest that disturbed lipid metabolism may significantly
310 contribute to the pathologic mechanisms in IPAH patients. Our simple FFA/lipid-ratios might be useful
311 in the diagnosis and clinical management of PH patients and might even serve as surrogate endpoints
312 in future clinical trials.

313 Classical machine learning using RF and XGboost showed that metabolic differences hold a
314 high potential for diagnostic biomarkers. Both approaches were able to overcome typical technical MS-
315 specific problems such as batch effects and intensity jumps between measurements, which usually
316 require drift correction, suggesting that such labour-intensive procedures are not necessary if PH is to
317 be detected. The same is true for our easily applicable FFA/lipid-ratios that performed comparably well
318 with drift-corrected and non-corrected metabolomics data, suggesting that forming such a ratio corrects
319 for batch effects and drifts in the metabolomics dataset as well as for inter-individual variability of
320 patients' lipid metabolism and lifestyle.

321 Our FFA/lipid-ratios performed very well in both PH diagnosis and survival prediction. Their
322 diagnostic performance even outperformed RF and XGBoost models, especially in terms of sensitivity.
323 In addition, the results were stable despite the use of different sample types such as serum, heparin and
324 EDTA plasma from three different centers, a very important prerequisite for broad applicability in
325 routine diagnostics. The performance was also stable when training and validation cohort were not split
326 by center but 70% to 30% balanced by age, BMI, sex and class. The FFA/lipid-ratios are easy to measure
327 and fully explainable compared to machine learning models, which is advantageous for future studies
328 and regulatory approval processes for *in vitro* diagnostics (IVD).

329 Survival prediction is an important tool in the management of PAH patients. Several clinical
330 scores have been established, with FPHR4P and COMPERA2.0 representing most recent developments
331 derived from large databases^{20,21}. The FPHR4P²⁰ score estimates prognosis based on WHO FC, 6MWD,
332 CI, and RAP, while COMPERA2.0²¹ is based on non-invasive parameters, only (WHO FC, 6MWD,
333 NT-pro-BNP). RATIO1 showed an age-dependency that was comparable to both clinical scores. Most
334 importantly, both clinical scores gained notably in predictive power when combined with RATIO1.
335 This suggests that FFA/lipid-ratios represent an independent, non-invasive prognostic factor that
336 combines favourably with established prognostic PH scores.

337 **Strengths and limitations**

338 Strengths of this study include exploration of primary IPAH small PA vessels, with mechanistic
339 insight in the effects of FFA on PASMC and PAEC, a broad metabolomics approach, sampling and
340 processing conditions suitable for routine clinical practice, inclusion of a disease control group,
341 comprehensive clinical assessment, use of machine learning, and development of diagnostic and
342 predictive FFA/lipid-ratios. As a limitation, we had access to a small number of patients and controls.
343 This may have been compensated by a profound clinical characterization of the patients, including
344 RHC, coupled with long follow-up times for survival analysis and the 70% to 30% balanced split test,
345 confirming the results. Another limitation is that FPHR4p and COMPERA2.0 have been derived from
346 PAH patients while we used them for all available patients including PH associated with left heart and
347 lung diseases. This may have introduced a bias into the prognostic performance of these scores,
348 however, this bias relates to the scores and our new markers in the same way. It may be seen as a
349 limitation, that blood samples were collected along with clinical routine blood draws, without
350 standardized fasting or other control measures, however, this may also represent a strength of our study
351 as it suggests robustness of the results. All metabolic measurements were based on high-resolution mass
352 spectrometry, a very sensitive and exact method, yet slow, expensive and work-intensive. However, our
353 FFA/lipid-ratios allow for a simplified approach that is easily available.

354 **Outlook**

355 Future studies including larger numbers of patients with a balanced group distribution and more
356 patients with early pulmonary hypertension and less impaired right ventricular function and longitudinal
357 studies are warranted to investigate the value of metabolic markers for patient management.

358 **Conclusions**

359 Based on our mechanistic insights into the metabolic changes in small PA, and our machine
360 learning approaches, our FFA/lipid-ratios identified PH patients with a high accuracy and were
361 significantly associated with prognosis. This may point to novel diagnostic tools and possibly also to
362 new therapeutic targets. If implemented into the management strategy for PAH patients, this might
363 inform therapy decisions to improve outcomes of PAH therapy.

364 **Supplemental Information**

365 Supplemental Information can be found attached to this publication.

366 **Materials Availability**

367 This study did not generate new unique reagents.

368 **Data and Code Availability**

369 The author declare that all data supporting the findings in this study are available in the online
370 supplementary data 1 and online repositories. Mass spectrometric data have been deposited in
371 <https://zenodo.org> under doi: 10.5281/zenodo.7857706. Data is provided de-identified and is available
372 immediately after publication with no end for those who wish to access the data for any purpose. The
373 provided *Sample_Name* in the online supplementary data 1 links to the file names in the online
374 repository and are unsuitable to identify single patients. The primary key is only known to part of the
375 study team. Machine learning code is available immediately with no end for those who wish to access
376 for any purpose on Github: <https://github.com/HelgaLudwig/PHMetab>.

377 **Author contributions**

378 Conceptualisation, NB, BMN, TP, HO, AO; Data curation, NB, BMN, EZ, HL, UB, HO, AO;
379 Formal analysis, NB, BMN, EZ, HL, UB, HO, AO; Funding acquisition, NB, TP, HO, AO;
380 Investigation, NB, BMN, EZ, VF, CN, VB, HO, AO; Methodology, NB, BMN, EZ, CN, AO, HO;
381 Project administration, NB, BMN, UB, VF, KH, SU, TJL, HO, AO; Resources, NB, BN, EZ, CM, HL,
382 UB, KH; SU, TJL, TP, HO, AO; Software, NB, HL; Supervision, NB, EZ, UB, HO, AO; Validation,
383 NB, BN, EZ, HL, VF, CN, VB, SU, TJL, HO, AO; Visualisation, NB, BMN, HL, CN, VB, AO; Writing
384 – original draft, NB, BAM, HO, AO; Writing – Review & Editing, all authors;

385 **Acknowledgements**

386 We are very grateful for the excellent technical assistance from Elisabeth Blanz, Sabine
387 Halsegger, Daniela Kleinschek, Jessica Schweiger, Yasemin Gassner, Gert Trausinger and Edgar
388 Gander. We express our heartfelt gratitude to Gabor Kovacs, Saskia Trescher, Pablo López-García,
389 Sophie Narath, Michael Pienn and Peter Wolf for their valuable discussions and helpful advices.

390 **Funding**

391 NB, TP disclose that part of this work has been carried out with the K1 COMET Competence
392 Center CBmed, which is funded by the Federal Ministry of Transport, Innovation and Technology; the
393 Federal Ministry of Science, Research and Economy; Land Steiermark (Department 12, Business and
394 Innovation); the Styrian Business Promotion Agency; and the Vienna Business Agency. The COMET

395 program is executed by the Österreichische Forschungsförderungs GmbH FFG. VB is supported by the
396 Austrian Science Foundation (FWF, T1032-B34).

397 **Competing interests**

398 Several authors (NB, CM, AO, BMN, HO) are inventors of the patent “*Biomarker for the*
399 *diagnosis of pulmonary hypertension (PH)*” WO2017153472A1 (priority date 09.03.2016, granted in
400 US, KR, JP, pending in CA, EP, AU) being jointly held by CBmed GmbH, Joanneum Research
401 Forschungsgesellschaft mbH, Medical University Graz and Ludwig Boltzmann Gesellschaft GmbH.
402 The authors received no personal financial gain from the patent.

403 During work on this publication NB was partially employed at CBmed GmbH. TP is chief
404 scientific officer (CSO) of CBmed GmbH. EZ and CM were employed at Joanneum Research
405 Forschungsgesellschaft mbH. The employing companies provided support in the form of salaries,
406 materials and reagents but did not have any additional role in the study design, data collection and
407 analysis, decision to publish, or preparation of the manuscript.

408 VF received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or
409 educational events from Janssen, Chiesi, BMS, and Boehringer Ingelheim and support for attending
410 meetings, and/or travel from Janssen, MSD, and Boehringer Ingelheim outside the submitted work.

411 CN received support for attending meetings, and/or travel from Boehringer Ingelheim and
412 Inventiva pharma outside the submitted work.

413 BAM reports personal fees from Actelion Pharmaceuticals, Tenax and Regeneron, grants from
414 Deerfield Company, NIH (5R01HL139613-03, R01HL163960, R01HL153502, R01HL155096-01),
415 Boston Biomedical Innovation Center (BBIC), Brigham IGNITE award, Cardiovascular Medical
416 research Education Foundation outside the submitted work. BAM reports patent PCT/US2019/059890
417 (pending), PCT/US2020/066886 (pending) and #9,605,047 (granted) not licensed and outside the
418 submitted work.

419 SU received grants from the Swiss National Science Foundation, Zürich and Swiss Lung
420 League, EMDO-Foundation, Orpha-Swiss, Janssen and MSD all unrelated to the present work. SU
421 received consultancy fees and travel support from Orpha-Swiss, Janssen, MSD and Novartis unrelated
422 to the present work.

423 TJL reports grants for his institution from Acceleron Pharma, Gossamer Bio, Janssen-Cilag,
424 and United Therapeutics; personal fees and non-financial support from Acceleron Pharma,
425 AstraZeneca, Boehringer Ingelheim, Gossamer Bio, Ferrer, Janssen-Cilag, MSD, Orphacare, and Pfizer
426 outside the submitted work.

427 KH is a consultant at Medtronic Österreich GmbH outside the submitted work.

428 TP reports grants from AstraZeneca, Novo Nordisk, Sanofi paid to the Medical University of
429 Graz outside the submitted work. TP reports personal fees and nonfinancial support from Novo Nordisk
430 and Roche Diagnostics outside the submitted work.

431 HO reports grants from Bayer, Unither, Actelion, Roche, Boehringer Ingelheim, and Pfizer. HO
432 reports personal fees and non-financial support from Medupdate and Mondial, AOP, Astra Zeneca,
433 Bayer, Boehringer Ingelheim, Chiesi, Ferrer, Menarini, MSD, and GSK, Iqvia, Janssen, Novartis, and
434 Pfizer outside the submitted work.

435 AO received honoraria for presentations and support for attending meetings, and/or travel from
436 MSD outside the submitted work.

437 No conflict of interest, financial or otherwise, are declared by the authors HL and UB.

438

439

440

441 References

- 442 1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and
443 treatment of pulmonary hypertension. *Eur Respir J*; 61. Epub ahead of print January 2023. DOI:
444 10.1183/13993003.00879-2022.
- 445 2. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. *Lancet*
446 *Respir Med* 2016; 4: 306–322.
- 447 3. Vachiéry J-L, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease.
448 *European Respiratory Journal* 2019; 53: 1801897.
- 449 4. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and
450 hypoxia. *Eur Respir J*; 53. Epub ahead of print 2019. DOI: 10.1183/13993003.01914-2018.
- 451 5. Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in
452 patients with pulmonary hypertension: a retrospective cohort study. *Lancet Respir Med* 2020; 8:
453 873–884.
- 454 6. Douschan P, Kovacs G, Avian A, et al. Mild Elevation of Pulmonary Arterial Pressure as a
455 Predictor of Mortality. *Am J Respir Crit Care Med* 2018; 197: 509–516.
- 456 7. Farber HW, Miller DP, Poms AD, et al. Five-Year outcomes of patients enrolled in the REVEAL
457 Registry. *Chest* 2015; 148: 1043–54.
- 458 8. Zelt JGE, Sugarman J, Weatherald J, et al. Mortality trends in pulmonary arterial hypertension
459 in Canada: a temporal analysis of survival per ESC/ERS guideline era. *Eur Respir J*; 59. Epub
460 ahead of print June 2022. DOI: 10.1183/13993003.01552-2021.
- 461 9. Kräuter C, Reiter U, Kovacs G, et al. Automated vortical blood flow-based estimation of mean
462 pulmonary arterial pressure from 4D flow MRI. *Magn Reson Imaging* 2022; 88: 132–141.
- 463 10. Brittain EL, Talati M, Fessel JP, et al. Fatty acid metabolic defects and right ventricular
464 lipotoxicity in human pulmonary arterial hypertension. *Circulation* 2016; 133: 1936–1944.
- 465 11. Hemnes AR, Luther JM, Rhodes CJ, et al. Human PAH is characterized by a pattern of lipid-
466 related insulin resistance. *JCI Insight*; 4. Epub ahead of print 10 January 2019. DOI:
467 10.1172/jci.insight.123611.
- 468 12. Lewis GD, Ngo D, Hemnes AR, et al. Metabolic Profiling of Right Ventricular-Pulmonary
469 Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. *J Am Coll*
470 *Cardiol* 2016; 67: 174–189.
- 471 13. Rhodes CJ, Ghataorhe P, Wharton J, et al. Plasma Metabolomics Implicates Modified Transfer
472 RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.
473 *Circulation* 2017; 135: 460–475.
- 474 14. Nagy BM, Nagaraj C, Meinitzer A, et al. Importance of kynurenine in pulmonary hypertension.
475 *American Journal of Physiology-Lung Cellular and Molecular Physiology* 2017; 313: L741–
476 L751.
- 477 15. Nagy BM, Kovacs G, Torniyos A, et al. No indication of insulin resistance in idiopathic PAH
478 with preserved physical activity. *European Respiratory Journal*; 55. Epub ahead of print 1 May
479 2020. DOI: 10.1183/13993003.01228-2019.
- 480 16. Wertheim BM, Wang RS, Guillermier C, et al. Proline and glucose metabolic reprogramming
481 supports vascular endothelial and medial biomass in pulmonary arterial hypertension. *JCI*
482 *Insight*; 8. Epub ahead of print 22 February 2023. DOI: 10.1172/jci.insight.163932.
- 483 17. Breiman L. Random forests. *Mach Learn* 2001; 45: 5–32.
- 484 18. Breiman L, Friedman JH (Jerome H), Olshen RA, et al. *Classification and regression trees*. 1st
485 ed. 1984.

- 486 19. Chen T, Guestrin C. XGBoost. In: *Proceedings of the 22nd ACM SIGKDD International*
487 *Conference on Knowledge Discovery and Data Mining*. New York, NY, USA: ACM, 2016, pp.
488 785–794.
- 489 20. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline
490 implementation in pulmonary arterial hypertension. *European Respiratory Journal*; 50. Epub
491 ahead of print 1 August 2017. DOI: 10.1183/13993003.00889-2017.
- 492 21. Hoepfer MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk
493 assessment model for pulmonary arterial hypertension. *European Respiratory Journal*; 60. Epub
494 ahead of print 1 July 2022. DOI: 10.1183/13993003.02311-2021.
- 495 22. Talati MH, Brittain EL, Fessel JP, et al. Mechanisms of Lipid Accumulation in the Bone
496 Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. *Am J Respir Crit Care Med*
497 2016; 194: 719–28.
- 498 23. Hemnes AR, Brittain EL, Trammell AW, et al. Evidence for right ventricular lipotoxicity in
499 heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2014; 189: 325–34.
- 500 24. Bhatt-Wessel B, Jordan TW, Miller JH, et al. Role of DGAT enzymes in triacylglycerol
501 metabolism. *Arch Biochem Biophys* 2018; 655: 1–11.
- 502 25. Chambers KT, Cooper MA, Swearingen AR, et al. Myocardial Lipin 1 knockout in mice
503 approximates cardiac effects of human LPIN1 mutations. *JCI Insight*; 6. Epub ahead of print
504 2021. DOI: 10.1172/jci.insight.134340.
- 505 26. Reue K. The lipin family: mutations and metabolism. *Curr Opin Lipidol* 2009; 20: 165–70.
- 506 27. Takeuchi K, Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin
507 enzymes in triglyceride synthesis. *Am J Physiol Endocrinol Metab* 2009; 296: E1195-209.
- 508 28. Paulin R, Michelakis ED. The Metabolic Theory of Pulmonary Arterial Hypertension. *Circ Res*
509 2014; 115: 148–164.
- 510 29. Pi H, Xia L, Ralph DD, et al. Metabolomic Signatures Associated With Pulmonary Arterial
511 Hypertension Outcomes. *Circ Res* 2023; 132: 254–266.
- 512 30. Harbaum L, Rhodes CJ, Wharton J, et al. Mining the Plasma Proteome for Insights into the
513 Molecular Pathology of Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* 2022;
514 205: 1449–1460.
- 515 31. Rhodes CJ, Wharton J, Swietlik EM, et al. Using the Plasma Proteome for Risk Stratifying
516 Patients with Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* 2022; 205: 1102–
517 1111.
- 518 32. Marra AM, Wei Y, Zhao H, et al. The Impact of Abnormal Lipid Metabolism on the Occurrence
519 Risk of Idiopathic Pulmonary Arterial Hypertension. *International Journal of Molecular*
520 *Sciences* 2023, Vol 24, Page 14280 2023; 24: 14280.

521
522
523

1 **Online Methods**

2 **Cohort Data Sources**

3 Results from the Graz Pulmonary Hypertension Registry (GRAPH) have been reported
4 previously^{1,2}. Briefly, the program uses a software application linked to the electronic health record for
5 documentation of all patients of the Division of Pulmonology at the Department of Internal Medicine
6 of the Medical University of Graz who gave written informed consent. Demographic, clinical,
7 echocardiographic, procedural, and hemodynamic data and blood samples are collected and tracked for
8 longitudinal outcomes. All hemodynamics were measured in a standardized fashion by the same
9 experienced team¹. Regularly scheduled quality checks of the registry are performed to ensure
10 completeness and accuracy. Written informed consent was obtained from all patients and the study was
11 conducted in line with the Helsinki declaration. The study was approved by the institutional ethics board
12 (identifier: 23-408ex10/11), and the study has been registered at ClinicalTrials.gov (NCT01607502).

13 The BioPersMed (Biomarkers of Personalised Medicine) project is designed as a single-centre,
14 prospective, observational cardiovascular risk study. Between 2010 and 2016, 1022 community
15 dwelling and asymptomatic individuals were regionally recruited and assessed biannually including a
16 standardized biospecimen acquisition³. Written informed consent was obtained from all patients and
17 the study was conducted in line with the Helsinki declaration.

18 **Cohort Study Population**

19 We retrospectively enrolled two consecutive cohorts of patients identified through our single-
20 center GRAPH registry and labelled them as GRAPH-Metabolomics (GRAPH-M).

21 The inclusion criteria for the first cohort were diagnosis of idiopathic pulmonary arterial
22 hypertension (IPAH) and absence of severe co-morbidities. Healthy sex- and age-matched subjects
23 served as a healthy controls (HC).

24 Inclusion criteria for the second cohort consisted of the following PH groups 1 – 4: 1) PAH, or
25 2) PH associated with heart disease, 3) PH associated with lung diseases (COPD, ILD), or 4) CTEPH.
26 The cohort of disease controls (DC) consisted of patients with airway or parenchymal lung disease or
27 patients with metabolic syndrome (hypertension, hypercholesterinemia and type 2 diabetes mellitus)
28 but no signs of elevated PAP. Healthy sex- and age-matched subjects served as a control group (HC).
29 The patients with the metabolic syndrome were selected from the BioPersMed cohort Graz.

30 All cohorts with the exception of patients with metabolic syndrome or HC underwent RHC. In
31 patients who underwent multiple RHCs, the first RHC was considered the index procedure and was the
32 only one included in the analysis. Patients were included in the analyses if data from a complete RHC
33 were available, including a resting value for mPAP, PAWP, CO, heart rate, systolic and diastolic PA

34 pressure, PVR and mixed venous oxygen saturation (SvO₂). We used the standard equation to calculate
35 the pulmonary vascular resistance with $PVR = (mPAP - PAWP)/CO$ expressed in WU.

36 **Validation Cohort**

37 This cohort comprised an international multicentric patient cohort. The inclusion criteria for the
38 validation cohort were the confirmed diagnosis of PAH and informed written consent at the home
39 institution. All participating centers were experienced centers of excellence for PH and all patients
40 underwent RHC in a standardized manner. Demographic, clinical, echocardiographic, procedural, and
41 hemodynamic data and blood samples were available as anonymized data. The sample collection was
42 approved by the local Ethics Committee in each local center (Regensburg University, ethics committee
43 No. 08/090 and cantonal ethical review board Zürich KEK 2010-0129; 2014-0214; 2017-0476).

44 **Cohort Outcomes**

45 The primary outcome was the confirmation of PH, defined as $mPAP \geq 25$ mmHg according to
46 the ERS/ESC guidelines from 2015⁴. The secondary endpoints included time to all-cause mortality with
47 data provided by Statistic Austria (single-centre registry Graz) and by the respective centers who
48 contributed to the validation cohort. A complete list of covariates analyzed in this study is provided in
49 the Supplementary Material (Fig. S3).

50 **Human lung tissue samples**

51 Human lung tissue samples were obtained from patients with IPAH who underwent lung
52 transplantation at the Department of Surgery, Division of Thoracic Surgery, Medical University of
53 Vienna, Vienna, Austria. The protocol and tissue usage were approved by the institutional ethics
54 committee (976/2010) and written patient consent was obtained before lung transplantation. The patient
55 characteristics included: age at the time of the transplantation, weight, height, sex, mPAP measured by
56 RHC, pulmonary function tests, as well as the medical therapy. The chest computed tomography scans
57 and RHC data were reviewed by experienced pathologists and pulmonologists to verify the diagnosis.
58 Healthy donor lung tissue was obtained from the same source. Donor/IPAH patient characteristics are
59 given in Supplementary Material (Table S2)**Fehler! Verweisquelle konnte nicht gefunden werden..**

60 **Lung histological Oil Red O staining**

61 The lipid accumulation of lung tissues was visualized by Oil Red O staining (Merck KGaA,
62 Darmstadt, Germany). Lung tissue was embedded in tissue freezing medium, were snap frozen at
63 -80 °C and sliced using a Leica CM 1900 cryostat (Leica Biosystems GmbH, Wetzlar, Germany) at a
64 thickness of 5 μ m per section. The slices were stained with Oil Red O working solution for 10 min,
65 differentiated in isopropanol for 5 min, and then washed with water at room temperature (20 – 25 °C)
66 (RT). The experiments were finished according to the manufacturer's instructions. The morphological

67 features of the tissues were assessed by hematoxylin-eosin (H&E) staining. The lipid in the tissue
68 observed by microscope.

69 **Laser capture microdissection of PA and RNA extraction**

70 Laser capture microdissection (LCM) of 10 donor lungs and 10 lungs from IPAH patients, as
71 well as mRNA isolation and cDNA synthesis were performed as previously described⁵. The intima and
72 media layers of PAs of 100 – 500 µm diameter were selected, marked and isolated with the Arcturus®
73 LCM System. Captured vessels were immediately transferred into RNA lysis buffer and were snap
74 frozen. RNeasy Micro Kit was utilized to isolate RNA (RNeasy Micro Kit, Qiagen, Hilden, Germany)⁶.

75 **qRT-PCR - laser capture microdissected human PA**

76 The expression of enzymes and transporters was analyzed with real-time quantitative (qRT)-
77 PCR using the QuantiFast SYBR PCR reagent (Qiagen, Hilden, Germany) according to Papp et al.
78 2019⁷. Primer pairs (Eurofins, Graz, Austria), summarized in Supplementary Material (Table S3), were
79 designed to span at least one exon-exon boundary to avoid the amplification of genomic DNA. The
80 specificity of all primers, as well as the length of the amplicon, were confirmed by melting curve
81 analysis and by running the products on 2% agarose gels, respectively.

82 **Cell Isolation and culture**

83 ***hPAECs***

84 hPAECs were either purchased from Lonza or isolated from donor lungs. For the isolation of
85 donor hPAECs, PA (< 2 mm in diameter) were isolated and the endothelium incubated with an
86 enzymatic mixture of collagenase, DNase and dispase in HBSS at RT⁸. Cell suspension was collected,
87 resuspended in Vasculife Complete SMC Medium and cultured in gelatin-coated T25 flasks at 37°C
88 and 5% CO₂. After reaching 70 – 80% confluency, cells were trypsinized, enriched by 3 consecutive
89 steps of CD31-selective magnetic-activated cell sorting technology and verified via morphological and
90 marker confirmation (smooth muscle actin SMA, fibronectin, vimentin, von-Willebrand Factor VWF,
91 smooth muscle myosin heavy chain and CD31). Surplus hPAECs were frozen (endothelial cell complete
92 medium containing 12% FCS and 10% DMSO) and stored in liquid nitrogen until further use. Passages
93 2–6 were used for the experiments. Detailed patient characteristics of isolated hPAECs can be found in
94 Supplementary Material (Table S4).

95 ***hPASMCs***

96 The isolation and culture of human hPASMCs was performed as previously reported⁹. After the
97 removal of the endothelial cell layer, the media was peeled away from the underlying adventitial layer
98 and cut into approximately 1–2 mm² sections, centrifuged and resuspended in Vasculife Complete

99 SMC Medium supplemented with 20% FCS and 0.2% antibiotics, then transferred to T75 flasks and
100 cultured at 37°C and 5% CO₂. After confluency of hPASMCM was formed, the cells were trypsinized
101 and either cultured in Vasculife Complete SMC medium supplemented with 10% FCS and 0.2%
102 antibiotics, or frozen (Vasculife Complete SMC Medium containing 15% FCS and 10% DMSO) and
103 stored in liquid nitrogen until further use. Passages 4–8 were used for the experiments. SMCs were
104 verified via morphological and marker confirmation (smooth muscle actin SMA, fibronectin, vimentin,
105 von-Willebrand Factor VWF, smooth muscle myosin heavy chain and CD31). Detailed patient
106 characteristics of isolated hPASMCMs can be found in Supplementary Material (Table S4).

107 **Lipid visualized by bodipy staining**

108 BODIPY (D3922, Invitrogen, Carlsbad, Calif, USA) (excitation wavelength 493 nm, emission
109 maximum 503 nm), was diluted in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 12
110 mM HPO₄²⁻/H₂PO₄⁻, pH 7.4) or DMSO at a concentration of 1 mg/mL and applied to the hPASMCMs
111 and hPAECs for 20 mins at RT. Fixed cells (4% paraformaldehyde at 37°C for 5 mins) were used.
112 Following fixation, samples were washed 3 times in PBS for 10 min. Sections were counterstained with
113 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) to visualize nuclei and covered
114 with glass cover slips. Images were taken using a laser scanning confocal microscope (Zeiss LMS 510
115 META; Zeiss, Jena, Germany) with Plan-Neofluar (×40 /1.3 Oil DIC) objective.

116 **Measuring cell metabolic state**

117 Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined
118 by the Seahorse XFp analyzer (Agilent, USA)¹⁰. hPASMCMs or hPAECs were plated onto cell culture
119 microplates on the day before the experiments and treated with 0.25mM FFA (a mix of oleate, FFA
120 16:0 and FFA C18 (2:1:1)) in Vasculife® complete Medium and incubated for 24 h. Cells were then
121 incubated in XF assay medium (Agilent), supplemented with 25 mmol/L glucose and 1 mmol/L
122 pyruvate (hPASMCMs) or 10 mmol/L glucose, 1 mmol/L pyruvate, and 2 mmol/L L-glutamine (hPAECs)
123 for 1 h at RT before the measurement. After the recording of the basal rates of OCR and ECAR, final
124 concentrations of 1 μmol/L oligomycin, 1 μmol/L carbonyl cyanide-4 (trifluoromethoxy)
125 phenylhydrazone, and 0.5 μmol/L rotenone and antimycin A for human hPASMCMs; 1 μmol/L
126 oligomycin, 1 μmol/L carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone, and 1 μmol/L rotenone
127 and antimycin A for human hPAECs were added (XF Cell Mito Stress Test Kit, Agilent) through the
128 instrument's injection ports to obtain proton leak, maximal respiratory capacity, and nonmitochondrial
129 respiration, respectively. Glycolytic capacity was measured using an XF Glycolysis Stress Test Kit
130 (Seahorse Bioscience). ECAR was determined after serial injection with 10 mmol/L D-glucose, 1
131 μmol/L oligomycin, and 100 mmol/L 2-deoxyglucose. All the assays were performed in triplicate and
132 normalized to protein content.

133 **Endothelial Barrier Function**

134 TEER served as an indicator of barrier function of endothelial cell monolayers. TEER was
135 determined using an electrical cell-substrate impedance sensor (ECIS) (Applied Biophysics, Troy, NY,
136 USA). Briefly, the endothelial cells are seeded in complete medium into (8W10E -PET arrays Applied
137 Biophysics, NY, USA) each well and allowed them to grow until they reached confluence. The FFA
138 (0.25 mM, a combination of FFA 18:1, FFA 16:0 and FFA 18:0 (2:1:1)) was applied for 24 hours before
139 the barrier disruption was initiated by addition of recombinant human thrombin.

140 **Proliferation**

141 To investigate the proliferative effect of FFA treatment on hPASMCs, the following protocol
142 was applied¹¹: 10 000 hPASMCs were seeded in 96-well plates; the following day the cells were starved
143 (VascuLife® Basal Medium, 0% FCS, 0.2% antibiotic/antimycotic) or kept under control conditions
144 (VascuLife® Basal Medium with 5% FCS; LifeLine Technology, Walkersville) for 12 h. Afterwards,
145 platelet-derived growth factor (PDGF)-BB was added and the proliferation of hPASMCs was
146 determined by [³H] thymidine (BIOTREND Chemikalien GmbH) incorporation, after 24 h of
147 incubation, as an index of DNA synthesis and measured as radioactivity by scintillation counting
148 (Wallac 1450 MicroBeta TriLux Liquid Scintillation Counter and Luminometer). To investigate the
149 effect of FFA (0.25 mM, a combination of oleate, FFA 16:0 and FFA 18:0 (2:1:1)) on hPASMCs, the
150 same number of cells was seeded and after 12 h of starvation, FFA and vehicle were added and the
151 proliferation of hPASMCs was determined as aforementioned. All experiments were performed in
152 quadruplicate.

153 **DAF-DM-mediated nitric oxide measurement**

154 Measurements were performed as previously described⁸. hPAECs were seeded in gelatin-
155 coated dark 96-well plates, starved for 2 h with Ringer's solution and loaded with 10 µm 4-Amino-5-
156 Methylamino-2',7'-Difluorofluorescein Diacetate (DAF-FM) for 30 min at 37°C. The cells were
157 stimulated with 5 µM acetylcholine (ACh) for the induction of nitric oxide measurement on
158 CLARIOstar Plus (BMG Labtech, Ortenberg, Germany) at Ex/Em = 495/515 nm. All the assays were
159 performed in quadruplicate and normalized to protein content.

160 **Plasma liquid chromatography–mass spectrometry metabolomics**

161 Metabolites were analysed by targeted hydrophilic interaction liquid chromatography–high
162 resolution mass spectrometry (HILIC-HRMS) metabolomics according to Bajad et al.¹² and samples
163 were processed according to Yuan et al.¹³ as described previously^{14,15}.

164 Samples from Graz were aliquoted and stored at the Biobank Graz. On the day of the processing
165 they were thawed in water ice bath on a slow rotary shaker (300 rpm) in < 10 min and vortexed shortly.

166 Aliquots of 100 μ l were precipitated in LoBind Eppendorf tubes with 400 μ l cold methanol (-80°C for
167 at least 4 h, kept on dry ice) and vortexed shortly. After the overnight precipitation at -80°C the samples
168 were centrifuged for 10 min at 14.000 g at 4°C and supernatants transferred to fresh LoBind Eppendorf
169 tubes. Supernatants were dried under nitrogen flow and stored at -80°C until all batches of the cohort
170 were finished. Extracts were reconstituted in 100 μ l 30% methanol/ H_2O , vortexed for 45 s and
171 centrifuged for 5 min at 14.000 g at 4°C . The supernatant was transferred into autosampler vials, and
172 equal aliquots from all samples were pooled for quality control (QC). All ready-to-measure extracts
173 were refrozen at -80°C prior to measurement. Every 24 h samples were freshly thawed at RT, vortexed,
174 spun down and added to the autosampler at 4°C .

175 Measurements were made in independent runs per cohort with samples in randomized order,
176 interspaced by according blanks, pooled QC samples and UltimateMix (UM, described previously¹⁶).
177 Pooled QC samples were generated independently for cohort 1 and 2, while QC was mixed for cohort
178 3 and 4. Cohorts 1 and 2 were extracted and measured in 1 batch, while cohorts 3 and 4 were randomly
179 divided into 6 batches for sample extraction and measured with daily thawed extracts to reduce
180 metabolite degradation.

181 Extracts were measured with a Dionex Ultimate 3000 high-performance liquid chromatography
182 (HPLC) setup (Thermo Fisher Scientific, USA) equipped with a NH_2 -Luna HILIC analytical column
183 and crudcatcher with an injection volume of 10 μ l and a 37 min gradient from aqueous acetonitrile
184 solution [(5% acetonitrile v/v), 20 mM ammonium acetate, 20 mM ammonium hydroxide, pH 9.45] as
185 eluent A (LMA) to acetonitrile as eluent B (LMB). Mass spectrometric detection was carried out with
186 a Q-ExactiveTM system (Thermo Fisher Scientific). Electrospray ionization (ESI) was used for negative
187 and positive ionization and masses between 70 and 1050 m/z were detected.

188 Raw data were converted to mzXML using msConvert (ProteoWizard Toolkit v3.0.5), and
189 target metabolites were extracted using the in-house developed tool PeakScout. Spectrum slices were
190 presented around the exact target mass (± 50 ppm) and retention time (± 3 min) in accordance with the
191 standards described by Sumner et al.¹⁷. For each target metabolite all peak area integrations were
192 manually confirmed in each sample. Molecular masses of target metabolites were taken from literature
193 and available online databases (HMDB, KEGG, Metlin)¹⁸⁻²⁰. In addition, pure substances of all
194 hydrophilic metabolites and selected lipophilic metabolites were run on the same system to obtain
195 accurate reference retention times and fragmentation spectra.

196 The analytical quality of all targeted metabolites was strictly graded to be suitable for
197 multivariate analysis and univariate analysis using the following parameters: deviation from target mass
198 < 5 ppm, mass difference range < 10 ppm, retention time standard deviation < 0.75 min, percentage of
199 missing values $< 30\%$, relative standard deviation in QC after drift correction $< 30\%$, and blank load in
200 QC $< 30\%$. Of 164 included metabolites, 11 metabolites were considered unsuitable for ROC analysis

201 due to lower signal intensity and lower consistency in repeated sample measurements (controls in
202 cohorts 3 and 4).

203 Analytical quality of samples, blanks, QC, and UM was graded by sample median, peak shapes,
204 retention time shifts, percentage of missing values < 30%, and position in the PCA scores plot. From
205 cohort 2, the first two UM and from cohort 4 the last four QC did not meet the quality criteria and were
206 therefore excluded.

207 **Statistical analysis**

208 Data visualisation and statistical analysis were performed with R v4.0.2 (R Core Team, 2020)
209 (using the packages readxl, openxlsx, stringr, dplyr, tidyr, doParallel, statTarget, car, colorspace,
210 RColorBrewer, ggplot2, ggforce, ggpmisc, ggpubr, scales, grid, ellipse, correlation, dendsort,
211 pheatmap, nlme, emmeans, missMDA, FactoMineR, mixOmics, MetaboAnalystR 3.0.3, survival,
212 survminer, pROC, caret, patchwork) and TIBCO Spotfire v12.5.0 (TIBCO, Palo Alto, CA). Graphpad
213 Prism v9 has been used to assess differences in the *in vitro* experiments.

214 Typically, MS results are relative and only comparable within the same run. However, recent
215 advances in drift correction allow to merge data for joint analysis. Peak areas without drift correction
216 were \log_{10} -transformed prior to all further analysis. The drift correction was based on the RF driven
217 algorithm that used QC measurements to model batch effects and drift for each metabolite with
218 *statTarget::shiftCor(., Frule = 0.7, ntree = 500, impute = "KNN", coCV = 100, QCspan = 0, degree*
219 *= 2)*²¹. The imputed, drift-corrected data were multiplied by 10^3 to make the numbers more readable
220 after \log_{10} -transformation. In the drift corrected, \log_{10} -transformed data all imputed values were
221 removed and data was trimmed by median absolute deviation (MAD) score²², assuming a normal
222 distribution (multiplication with 1.4826). Strong single outliers were removed with a very conservative
223 threshold of having an absolute MAD score > 4 (165 single values in 65 metabolites). Data for all
224 metabolites and samples is provided in Supplementary Data 1 with and without drift correction.

225 In order to ensure validity of drift correction and subsequent results, each measurement run was
226 first analysed independently with unsupervised multivariate (iPCA), supervised multivariate (OPLS-
227 DA) and univariate on \log_{10} -transformed data without drift correction (see Fig. S1). Next, drift
228 corrected, \log_{10} -transformed data from all runs was jointly analysed with the same methods. The drift
229 correction successfully removed the significant difference between measurement runs and notably
230 reduced the technical variability in all metabolites (Fig. S2). Additionally, no difference was observed
231 based on center or sample material type (Fig. S2). Replicate measurements of samples in different runs
232 were average on drift corrected data to yield one metabolome per patient for subsequent analysis one
233 metabolome per patient.

234 All reported p-values were adjusted for multiple testing according to Benjamini–Hochberg
235 (BH) denoted as p_{BH} (`stats::p.adjust()`)²³. Distribution and scedasticity were investigated with
236 Kolmogorov–Smirnov test (`stats::ks.test()`) and Brown–Forsythe Levene-type test
237 (`car::leveneTest()`)²⁴, respectively. After \log_{10} -transformation data was mostly normally distributed
238 with 91% of all metabolites without drift correction and 99% of all metabolites with drift correction
239 testing not significant ($p_{BH} > 0.05$). Analog, data was mostly homoscedastic with 79% without drift
240 correction and 80% with drift correction of all metabolites testing not significant ($p_{BH} > 0.05$).

241 For iPCA missing values were imputed with `missMDA::imputePCA(, ncp = 10)`²⁵ and analysis
242 was performed scaled and centred to unit variance (z-scaled) with `mixOmics::ipca(, scale = TRUE,`
243 `ncomp = 2, mode = "deflation")`²⁶.

244 For OPLS-DA missing values were imputed with `MetaboAnalystR::ImputeMissingVar(,`
245 `method = "knn_var")`²⁷, data was scaled and centred to unit variance (z-scaled) with
246 `MetaboAnalystR::Normalization(..., "AutoNorm")` and models were calculated with
247 `MetaboAnalystR::OPLSR.Anal(, reg = TRUE)` with a standard 7-fold cross-validation for the factor
248 *disease*. Model stability was additionally verified with 1000 random label permutations by
249 `MetaboAnalystR::OPLSDA.Permut(, num = 1000)`.

250 Pearson correlation were calculated for each metabolite (drift corrected, \log_{10} -transformed data)
251 against each numeric clinical parameter (untransformed) with `correlation::correlation()`²⁸. Results were
252 filtered to retain only metabolites and clinical parameters with at least one significant correlation
253 ($p_{BH} < 0.05$). Retained correlations were clustered by Lance-Williams dissimilarity update with
254 complete linkage using `stats::dist()` and `stats::hclust()`. Dendogram were sorted with
255 `dendsort::dendsort()`²⁹ at every merging point according to the average distance of subtrees and plotted
256 at the corresponding heat maps of Pearson R with `pheatmap::pheatmap()`³⁰.

257 For univariate analysis of significant changes within each metabolite for the factor *disease* (i.e.
258 PH vs. HC/DC) generalized least squares models were fitted with `nlme::gls()`^{31,32} without confounders
259 and with potential confounders (age, sex, BMI) by maximum likelihood. For analysis within each cohort
260 \log_{10} -transformed data was used, for joint analysis over all cohorts drift corrected, \log_{10} -transformed
261 data was used, thus constituting a nonlinear approach. The three most common potential confounders
262 (age, sex, BMI) were added stepwise in all possible combinations and model performances were
263 compared within each metabolite by lower AIC (Akaike information criterion; relative estimate of
264 information loss), higher log-likelihood (goodness of fit), significance in log-likelihood ratio test
265 comparing two models, quality of Q-Q plots, randomness in residual and direct comparison of t-ratios.
266 All models with any confounder combination showed significant influence ($p < 0.01$) on selected few
267 metabolites (13–39). The model with age + sex impacted most metabolites. However, a direct

268 comparison of t-ratio revealed a very small impact of age or sex correction on results, and according to
269 model parsimony models without confounders were reported throughout.

270 FFA/lipid-ratios were calculated with FFAs in the numerator and lipids in the denominator. The
271 numerators were all possible, summed (not weighed) combinations of up to six FFA from 11 FFAs
272 (most significant in univariate analysis PH versus HC/DC and best analytical quality): FFA C15:0,
273 FFA C16:2, FFA C16:1, FFA C17:1, FFA C17:0, FFA C18:3, FFA C18:2, FFA C18:1, FFA C19:1,
274 FFA C20:5 and FFA C20:1. The denominators were all possible, summed (not weighed) combinations
275 of up to four lipids from eight lipids (no significant change in univariate analysis and best analytical
276 quality): LPC 18:2, LPC 18:1, PC 36:4, PC 38:6, SM 34:2, SM 36:2, LPE 16:0, and LPE 18:1. The
277 combination of all possible summed FFA numerator and summed lipid denominator yielded a total of
278 240 570 different FFA/lipid-ratios. All used FFA and lipids had no missing values. The technical
279 variability RSD in QC was calculated for each FFA/lipid-ratio following the rules of error propagation
280 from the single metabolites RSD of QC in drift corrected, \log_{10} -transformed data. All FFA/lipid-ratios
281 were calculated once without and once with drift correction (both \log_{10} -transformed). Diagnostic
282 performance was tested by ROC analysis with $pROC::roc(..., algorithm = 2)^{33}$ based on our training
283 cohort. Test data like in machine learning approaches was not needed here because ratios are directly
284 calculated without any model training. Therefore logistic regression was performed fitting training data
285 with $stats::glm(..., family = "binomial")$. The performance was evaluated on the validation cohort
286 using $pROC::roc()$. The optimal threshold was determined with $pROC::coords(..., best.method =$
287 *"closest.topleft"*) to determine sensitivity and specificity.

288 Survival analysis used either times since sampling or times since diagnosis defining confirmed
289 death as endpoint while censoring all others at time of last known follow-up. Impact of all relevant
290 clinical parameters (untransformed), all single metabolites (drift corrected, \log_{10} -transformed data) and
291 best performing FFA/lipid-ratios (\log_{10} -transformed data without drift correction) was analysed.
292 FPHR4p scores were inverted so that higher values represent higher mortality risk. Numerical
293 parameters were split into *high* and *low* with *maxstat* as optimal cut-off for survival prediction as
294 determined by $survminer::surv_cutpoint(..., minprop = 0.3)^{34}$. Kaplan–Meier curves were fitted for
295 each category with $survival::survfit()$ ³⁵, differences were tested with $survminer::ggsurvplot()$ and plots
296 with time since diagnosis were truncated at 15 years for better comparability with times since baseline
297 (i.e. time since sampling). The Cox HR analysis³⁶ was calculated with $survminer::coxph()$ for the
298 confounders (age, sex, BMI), the COMPERA 2.0 score, FPHR4p, and RATIO1 alone or in
299 combinations. Numeric factors were categorized into *high* and *low* same as for Kaplan–Meier curves.
300 The combination of RATIO1 with the FPHR4p or COMPERA 2.0 score was done additively with the
301 same weighting on scaled values from 0 to 1, rescaling after addition.

302 Data visualisation and calculation of the machine learning and Cox
303 HR analysis was performed with Python 3.9 (using the packages pandas, numpy, seaborn, sklearn,
304 matplotlib, xgboost)³⁷⁻⁴⁰.

305 For machine learning, the package sklearn⁴¹ was used for the random forest (RF) and package
306 xgboost for the XGBoost⁴² implementation, for better reproducibility a fixed random seed was set. Data
307 was normalized with mean 0 and variance 1. A hyperparameter search for *number of trees* {101, 301,
308 1001, 2001, **3001**} and *depth* {5, 10, 100, 200, **300**} for RF and *eta* {0.1, **0.01**, 0.001}, *depth* {5, **10**, 100,
309 200, 300} and *n_estimators* {101, 301, 1001, 2001, **3001**} for XGBoost was conducted with finally used
310 hyperparameters highlighted in bold. Models were trained on training cohort data, which was randomly
311 further divided five times into 80% for training and 20% for testing (stratified by class, age, sex, with
312 non-overlapping test data). Trained models were validated with the external validation cohort, which
313 had no data overlap with the training cohort.

314 Additionally to the original split by center (i.e. city of sample origin), all samples were
315 artificially split into 70% training and 30% validation sets with balanced distributions in age, BMI, sex
316 and class (PH/DC/HC) to overcome the potential bias from the unequal distribution of age, BMI, sex
317 and class in the original training and validation cohorts by center. The distribution of age and BMI was
318 equal according to a t-test as well as for sex and class (PH/HC/DC) according to a χ^2 test ($p > 0.2$). All
319 machine learning and FFA/lipid-ratio ROC analysis were repeated for these 70:30 training and
320 validation sets.

321 Language editing was aided by the artificial intelligence tool <https://instatext.io/> (last accessed
322 November 2023).

323

324

325

326 Online References

- 327 1. Kovacs G, Avian A, Wutte N, et al. Changes in pulmonary exercise haemodynamics in
328 scleroderma: a 4-year prospective study. *Eur Respir J*; 50. Epub ahead of print 2017. DOI:
329 10.1183/13993003.01708-2016.
- 330 2. Kovacs G, Avian A, Bachmaier G, et al. Severe Pulmonary Hypertension in COPD: Impact on
331 Survival and Diagnostic Approach. *Chest* 2022; 162: 202–212.
- 332 3. Haudum CW, Kolesnik E, Colantonio C, et al. Cohort profile: ‘Biomarkers of Personalised
333 Medicine’ (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria
334 to evaluate novel biomarkers in cardiovascular and metabolic diseases. *BMJ Open* 2022; 12:
335 e058890.
- 336 4. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and
337 treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of
338 Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European
339 Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital
340 Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur*
341 *Respir J* 2015; 46: 903–75.
- 342 5. Hoffmann J, Wilhelm J, Marsh LM, et al. Distinct differences in gene expression patterns in
343 pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic
344 pulmonary fibrosis with pulmonary hypertension. *Am J Respir Crit Care Med* 2014; 190: 98–
345 111.
- 346 6. Nagaraj C, Tabeling C, Nagy BM, et al. Hypoxic vascular response and ventilation/perfusion
347 matching in end-stage COPD may depend on p22phox. *Eur Respir J*; 50. Epub ahead of print 1
348 July 2017. DOI: 10.1183/13993003.01651-2016.
- 349 7. Papp R, Nagaraj C, Zabini D, et al. Targeting TMEM16A to reverse vasoconstriction and
350 remodelling in idiopathic pulmonary arterial hypertension. *Eur Respir J*; 53. Epub ahead of print
351 1 June 2019. DOI: 10.1183/13993003.00965-2018.
- 352 8. Skofic Maurer D, Zabini D, Nagaraj C, et al. Endothelial Dysfunction Following Enhanced
353 TMEM16A Activity in Human Pulmonary Arteries. *Cells*; 9. Epub ahead of print 28 August
354 2020. DOI: 10.3390/CELLS9091984.
- 355 9. Stulnig G, Frisch MT, Crnkovic S, et al. Docosahexaenoic acid (DHA)-induced heme
356 oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells.
357 *Atherosclerosis* 2013; 230: 406–413.
- 358 10. Kikuchi N, Satoh K, Kurosawa R, et al. Selenoprotein P Promotes the Development of
359 Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target. *Circulation* 2018; 138:
360 600–623.
- 361 11. Biasin V, Marsh LM, Egemnazarov B, et al. Meprin β , a novel mediator of vascular remodelling
362 underlying pulmonary hypertension. *J Pathol* 2014; 233: 7–17.
- 363 12. Bajad SU, Lu W, Kimball EH, et al. Separation and quantitation of water soluble cellular
364 metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. *J*
365 *Chromatogr A* 2006; 1125: 76–88.
- 366 13. Yuan M, Breitkopf SB, Yang X, et al. A positive/negative ion-switching, targeted mass
367 spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue.
368 *Nat Protoc* 2012; 7: 872–81.
- 369 14. Fröhlich EE, Farzi A, Mayerhofer R, et al. Cognitive impairment by antibiotic-induced gut
370 dysbiosis: Analysis of gut microbiota-brain communication. *Brain Behav Immun* 2016; 56: 140–
371 155.

- 372 15. Mueller KM, Hartmann K, Kaltenecker D, et al. Adipocyte Glucocorticoid Receptor Deficiency
373 Attenuates Aging- and Hfd-Induced Obesity, and Impairs the Feeding-Fasting Transition.
374 *Diabetes* 2017; 66: 272–286.
- 375 16. Vogel FCE, Bordag N, Zügner E, et al. Targeting the H3K4 Demethylase KDM5B Reprograms
376 the Metabolome and Phenotype of Melanoma Cells. *Journal of Investigative Dermatology* 2019;
377 139: 2506-2516.e10.
- 378 17. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical
379 analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI).
380 *Metabolomics* 2007; 3: 211–221.
- 381 18. Guijas C, Montenegro-Burke JR, Domingo-Almenara X, et al. METLIN: A Technology
382 Platform for Identifying Knowns and Unknowns. *Anal Chem* 2018; 90: 3156.
- 383 19. Kanehisa M, Sato Y, Kawashima M, et al. KEGG as a reference resource for gene and protein
384 annotation. *Nucleic Acids Res* 2016; 44: D457–D462.
- 385 20. Wishart DS, Feunang YD, Marcu A, et al. HMDB 4.0: The human metabolome database for
386 2018. *Nucleic Acids Res* 2018; 46: D608–D617.
- 387 21. Luan H, Ji F, Chen Y, et al. statTarget: A streamlined tool for signal drift correction and
388 interpretations of quantitative mass spectrometry-based omics data. *Anal Chim Acta* 2018; 1036:
389 66–72.
- 390 22. Leys C, Ley C, Klein O, et al. Journal of Experimental Social Psychology Detecting outliers :
391 Do not use standard deviation around the mean, use absolute deviation around the median.
392 *Experimental Social Psychology* 2013; 4–6.
- 393 23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
394 Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*
395 *(Methodological)* 1995; 57: 289–300.
- 396 24. Brown MB, Forsythe AB. Robust Tests for the Equality of Variances. *J Am Stat Assoc* 1974;
397 69: 364.
- 398 25. Husson F, Josse J. missMDA: Handling Missing Values with Multivariate Data Analysis. *R*
399 *package version 1.8.2.*, <http://cran.r-project.org/package=missMDA> (2015).
- 400 26. Rohart F, Gautier B, Singh A, et al. mixOmics: An R package for ‘omics feature selection and
401 multiple data integration. *PLoS Comput Biol* 2017; 13: e1005752.
- 402 27. Pang Z, Chong J, Li S, et al. MetaboAnalystR 3.0: Toward an Optimized Workflow for Global
403 Metabolomics. *Metabolites* 2020; 10: 186.
- 404 28. Makowski D, Ben-Shachar M, Patil I, et al. Methods and Algorithms for Correlation Analysis
405 in R. *J Open Source Softw* 2020; 5: 2306.
- 406 29. Sakai R, Biederstedt E. dendsort: modular leaf ordering methods for dendrogram representations
407 in R. Epub ahead of print 2021. DOI: 10.12688/f1000research.4784.1.
- 408 30. Kolde R. pheatmap: Pretty Heatmaps. *R package version 1.0.12*, [https://CRAN.R-](https://CRAN.R-project.org/package=pheatmap)
409 [project.org/package=pheatmap](https://CRAN.R-project.org/package=pheatmap) (2019, accessed 13 February 2023).
- 410 31. Pinheiro J, Bates D, R Core Team. nlme: Linear and Nonlinear Mixed Effects Models,
411 <https://CRAN.R-project.org/package=nlme> (2022, accessed 13 February 2023).
- 412 32. Pinheiro J, Bates D, DebRoy S, et al. nlme: Linear and Nonlinear Mixed Effects Models. *R*
413 *package version 3.1-122* 2015; 3: 57.
- 414 33. Robin X, Turck N, Hainard A, et al. pROC: An open-source package for R and S+ to analyze
415 and compare ROC curves. *BMC Bioinformatics* 2011; 12: 77.
- 416 34. Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using ‘ggplot2’,
417 <https://CRAN.R-project.org/package=survminer> (2021, accessed 13 February 2023).

- 418 35. Therneau TM. Package for Survival Analysis in R, [https://CRAN.R-](https://CRAN.R-project.org/package=survival)
419 [project.org/package=survival](https://CRAN.R-project.org/package=survival) (2021, accessed 13 February 2023).
- 420 36. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society: Series B*
421 *(Methodological)* 1972; 34: 187–202.
- 422 37. Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. *Nature* 2020;
423 585: 357–362.
- 424 38. McKinney W. Data Structures for Statistical Computing in Python. In: *PROC. OF THE 9th*
425 *PYTHON IN SCIENCE CONF. (SCIPY 2010)*. 2010, pp. 56–61.
- 426 39. Waskom M, Botvinnik O, O’Kane D, et al. *mwaskom/seaborn: v0.8.1* (September 2017). Epub
427 ahead of print 2017. DOI: 10.5281/zenodo.883859.
- 428 40. Hunter JD. Matplotlib: A 2D Graphics Environment. *Comput Sci Eng* 2007; 9: 90–95.
- 429 41. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in Python.
430 *Journal of Machine Learning Research* 2011; 12: 2825–2830.
- 431 42. Chen T, Guestrin C. XGBoost. In: *Proceedings of the 22nd ACM SIGKDD International*
432 *Conference on Knowledge Discovery and Data Mining*. New York, NY, USA: ACM, 2016, pp.
433 785–794.
- 434
435
436

437 Supplementary Figures




Fig. S1. PH is associated with a strong metabolic shift in every measurement run. (A) iPCA scores plot representing the metabolic profile of each sample as a dot. The proximity of the dots indicates the similarity of the subjects' metabolomes. Clear group separation by PH is visible along the first and/or second component for each run and when all runs are jointly analyzed. (B) To A corresponding loadings plot in which each dot represents the contribution of the metabolite to the group separation observed in the scores plot. Free fatty acids (FFA, yellow circles) strongly drive the group separation and are increased in PH patients. (C) OPLS-DA maximizes the group difference from PH to HC/DC and the resulting scores plot represents, as in A, with dots the metabolome of each subject. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. The difference between the metabolome of PH and HC/DC was significant ($Q^2 > 50\%$, $p < 0.001$). (D) Volcano plot of univariate analysis highlighting significant ($p_{BH} < 0.05$, grey horizontal line) and strong (absolute contrast ratio > 0.25 , grey vertical lines) increase in FFAs. For all methods 164 known metabolites and all samples from the measurement run per cohort ($n_1 = 16$, $n_2 = 33$, $n_3 = 118$, $n_4 = 109$) on \log_{10} -transformed data was used. In run 4 measurement all HC samples from run 3 were repeated to evaluate reproducibility of samples across measurement runs.




Fig. S2. Drift correction improves data quality enabling a unified analysis of all 4 measurement runs. (A, B) Plot of the sample's median signal intensity of all metabolites versus the sequence of measurement with measurements runs being separated by vertical black lines. (A) The QC samples (grey x) fluctuate within each measurement (= drift), while the batch effect is well visible as signal intensity jumps between the measurements. (B) Drift correction with an RF-based algorithm on QC samples removed drift and batch effects from the median sample intensity. (C, E, G, H, I, J) iPCA scores plots plot representing the metabolic profile of each sample as a dot. The proximity of the dots indicates the similarity of the metabolomes. Lines connect replicate measurements from same samples. Note (C, G, H) are the same iPCA model highlighting different biological factors. Analog (E, I, J) are the same iPCA model. (C) A clear group separation by measurement run is well visible between all 4 runs, with runs 3 and 4 being more similar due to the back to back measurement and shared HC and QC samples. (D) Drift correction removes the separation by measurement run. (D, F) OPLS-DA maximizes the differences between runs 1 to 4 and the resulting scores plot represents, as in C, with dots the metabolome of each sample. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. (D) All 4 measurement runs were highly significantly ($Q^2 > 50\%$, $p < 0.001$) different before drift correction and (F) become non-significant after drift correction. (G, I) The observed group separation by sample origin (study center) before drift correction was significantly reduced after drift correction. (H, J) The observed group separation by sample material type before drift correction was significantly reduced after drift correction. (K) The strong reduction of the technical variability over all 4 runs after drift corrections shows how well the RF-based algorithm reduced technical noise. All plots are based on 164 known metabolites and all samples from the measurement run per cohort ($n_1 = 16$, $n_2 = 33$, $n_3 = 118$, $n_4 = 109$). A, C, D, G, H used \log_{10} -transformed. B, E, F, I, J used \log_{10} -transformed, drift corrected data.




Fig. S3. Correlation of selected metabolites with clinical parameters in the training cohort. (A) Volcano plot of all pairwise Pearson correlations of all 164 metabolites (drift corrected, \log_{10} -transformed data) versus 43 clinical parameters highlighting strong (absolute $R > 0.5$, grey vertical lines) and significant ($p_{BH} < 0.05$, grey horizontal line) correlations. Based on training cohort ($n = 169$). (B) Heatmaps with hierarchical clustering of the respective metabolite vs. clinical parameter. Pearson correlations were filtered to keep only rows and columns with at least

one sig. correlation. All pairwise Pearson correlation results can be found in Supplementary Data 1. Uric acid and creatinine were measured as metabolite and were part of routine hematology. Accordingly, these parameters show the strongest, most significant correlations. (C) Overview of all investigated numeric clinical parameters correlated in (A, B) with all metabolites, listing their short names, explanations and units.

438




Fig. S4. Data split has little impact on performance of RF, XGBoost or Ratios in predicting PH. The data was split 70:30 into trainings (n = 163, solid line) and validation set (n = 70, dashed line) balanced by age, BMI, sex and class, data was \log_{10} -transformed. (A) ROC plots of RF (green) and XGBoost (blue) trained with data from training cohort predicting class in validation cohort based on 153 metabolites and 95% confidence intervals marked by ribbons. (B) The ROC plots of the three best FFA/lipid-ratios and 95% confidence intervals marked by ribbons. (C) Plot of model performance metrics specificity, sensitivity and balanced accuracy for RF, XGBoost, and the three best FFA/lipid-ratios when based on either training (circles) or validation (diamonds) cohorts only or all available data (squares).

439




Fig. S5. A quarter million of FFA/lipids-ratios could diagnose PH. (A-F) The histograms summarize the AUCs of the ROC analysis for all 240 570 FFA/lipid-ratios in each data type and split. The histogram of ROC analysis performance AUC for all possible FFA/lipid-ratios exhibits a tight distribution showing that all ratios performed similarly good. (G-I) Direct comparison of AUCs between the trainings and validation cohorts. (A, B, G, H) ROC analysis within the training cohort (cohort 1, 2, 3 n = 169) of the original split by centers benchmarked against the (D, E, G, H) validation cohort (cohort 4 n = 64). (C, I) ROC analysis within the trainings set (n = 163) of the 70:30 split (balanced by age, BMI, sex and class PH/DC/HC) and the (F, I) validation set (n = 70). (A, D, G) are based

on drift \log_{10} -transformed, drift corrected data while (B, C, E, F, H, I) are based on \log_{10} -transformed data. (J) The histogram of the calculated technical error ratio for each ratio exhibits a tight distribution around 5% total technical relative variability showing. The grey vertical line marks the maximally acceptable technical variability cut-off for measurement methods in clinical routine laboratories. (K) The AUC from (A) and (B) are very similar to each other, confirming that the drift correction only slightly influences ROC analysis. (L) The AUC from (B) and (C) are very similar to each other, confirming that the split by center delivers very similar results to the 70:30 balanced split. Axes were scaled to exclude empty regions in (A-I, K, L), especially for AUC < 0.6 which have no to very little predictive value. (M) Overview of top performing ratios for the original split by center with and without drift correction. The equations for the in both datasets top 3 ratios are given.

440




Fig. S6. Survival analysis of covariates age, sex and BMI and linear correlation of top three RATIOS with clinical parameters. (A) Cox HR analysis for survival since baseline and the 95% confidence interval with statistical significance coded as not significant (ns); * p < 0.05; ** p < 0.01; *** p < 0.001. Higher age alone and in the tri-factor model was a significant risk factor while BMI and sex were slightly elevated but never significant. (B) Kaplan–Meier curves of survival times since baseline by age, sex or BMI. Age and BMI cut-offs were optimized with maxstat. (C) Heatmaps with hierarchical clustering of pairwise Pearson correlations of the top three RATIOS (\log_{10} -transformed data) versus 43 clinical parameters. All PH patients with survival times and both clinical scores were included (n = 91). All pairwise Pearson correlation results can be found in Supplementary Data 1.

441




Fig. S7. Survival analysis of established clinical risk factors and top metabolites. Kaplan–Meier curves analyzing survival times since baseline either for all PH patients or PH patients with both clinical scores available ($n = 91$). The stated cut-off for survival prediction was optimized with maxstat. **(A)** Survival of PH patients significantly decreases with known clinical risk factors such as higher WHO FC classes, lower 6MWD, higher NT-pro-BNP levels, and higher uric acid levels.

443 Supplementary Tables

444 **Table S1: Subject characteristics with medians \pm 95% confidence intervals within measurement runs of the training**
445 **cohort**

	run 1		run 2			run 3		
	HC (n=8)	PH (n=8)	HC (n=12)	DC (n=9)	PH (n=12)	HC (n=45)	DC (n=21)	PH (n=52)
Age at sampling, y	57.0 \pm 8.8	58.5 \pm 9.0	70.5 \pm 10.8	56.0 \pm 10.1	63.0 \pm 9.3	58.0 \pm 2.6	60.0 \pm 5.7	66.5 \pm 3.7
Female:male (ratio)	7:1 (7:1)	7:1 (7:1)	11:1 (11:1)	7:2 (3.5:1)	11:1 (11:1)	26:19 (1.4:1)	13:8 (1.6:1)	30:22 (1.4:1)
BMI kg/m ²	22.6 \pm 2.7	24.8 \pm 3.4	25.8 \pm 3.0	30.7 \pm 5.5	25.5 \pm 3.5	24.1 \pm 1.0	22.5 \pm 3.2	25.7 \pm 1.3
Diagnosis since y	-	3.0 \pm 5.9	-	-	6.0 \pm 4.0	-	8.0 \pm 2.1	0.0 \pm 1.1
<i>Pulmonary hemodynamics from RHC</i>								
mPAP (mmHg) mean pulmonary arterial pressure	-	45.0 \pm 7.7	-	-	41.5 \pm 5.8	-	22.0 \pm 0.8 [#]	41.0 \pm 3.1
PAWP (mmHg) pulmonary arterial wedge pressure	-	10.0 \pm 4.2	-	-	5.5 \pm 1.7	-	9.5 \pm 0.3 [#]	10.0 \pm 1.6
CO (L/min) cardiac output	-	4.1 \pm 1.6	-	-	4.3 \pm 0.8	-	3.9 \pm 0.4 [#]	4.6 \pm 0.5
CI (L/min/m ²) cardiac index	-	2.3 \pm 0.7	-	-	2.5 \pm 0.5	-	2.4 \pm 0.3 [#]	2.6 \pm 0.2
PVR (WU) pulmonary vascular resistance	-	8.3 \pm 3.7	-	-	8.9 \pm 3.1	-	3.2 \pm 0.3 [#]	6.0 \pm 1.2
RAP (mmHg) right arterial pressure	-	5.0 \pm 3.8	-	-	5.0 \pm 2.4	-	5.0 \pm 1.1 [#]	7.0 \pm 1.5
<i>Clinical data</i>								
6MWD (m) 6-min walk distance	-	338 \pm 96	-	-	431 \pm 149	-	454 \pm 50	317 \pm 32
WHO FC world health organisation functional class	-	3.0 \pm 0.6	-	-	3.0 \pm 0.5	-	2.0 \pm 0.3	3.0 \pm 0.2
FEV1 (% predicted) forced expiration 1 s	-	83.0 \pm 16.5	-	-	82.5 \pm 12.9	-	51.5 \pm 12	68.5 \pm 6.7
FVC (% predicted) forced vital capacity	-	90.9 \pm 18.0	-	-	97.6 \pm 14.8	-	63.8 \pm 8.2	78.0 \pm 6.5
FEV1/FVC (% predicted)	-	73.3 \pm 6.0	-	-	78.3 \pm 6.5	-	56.3 \pm 10.3	73.2 \pm 3.9
TLC (% predicted) total lung capacity	-	95.7 \pm 12.5	-	-	103.1 \pm 9.4	-	103.0 \pm 13.2	92.0 \pm 5.2
DLCO cSB (% predicted) single-breath CO diffusing capacity, hemoglobin corrected	-	69.5 \pm 8.4	-	-	65.4 \pm 9.5	-	49.6 \pm 9.6	56.4 \pm 8.2
DLCO cVA (% predicted) CO diffusing capacity alveolar volume, hemoglobin corrected	-	74.6 \pm 14.1	-	-	60.6 \pm 20.8	-	70.0 \pm 9.6	71.0 \pm 7.8
RDW (%) red cell distribution width	-	15.5 \pm 1.1	-	-	14.4 \pm 0.9	-	14.0 \pm 0.9	15.7 \pm 1.0
NT-proBNP (pg/mL)	-	508 \pm 1197	-	-	263 \pm 1122	-	98 \pm 47	1100 \pm 1112.2
Uric acid (mg/dL)	-	5.7 \pm 1.4	-	-	5.7 \pm 1.6	-	5.0 \pm 0.6	6.2 \pm 0.7
Creatinine (mg/dL)	-	0.92 \pm 0.17	-	-	1.02 \pm 0.19	-	0.80 \pm 0.11	1.04 \pm 0.17
Bilirubin total (mg/dL)	-	0.61 \pm 0.25	-	-	0.57 \pm 0.26	-	0.40 \pm 0.16	0.70 \pm 0.17

446 [#]based on 4 patients, not representative

447 **Table S2: Characteristics of patients with IPAH and healthy donors used for laser capture-microdissection of PA.**

	ID	Age	Sex		ID	Age	Sex	mPAP
Donor	1	[50-59]	male	IPAH	1	[30-39]	female	50
	2	[70-79]	female		2	[30-39]	female	88
	3	[50-59]	female		3	[18-29]	female	56
	4	[30-39]	male		4	[18-29]	female	69
	5	[18-29]	female		5	[50-59]	male	66
	6	[50-59]	male		6	[18-29]	male	74
	7	[18-29]	male		7	[50-59]	male	65
	8	[70-79]	female		8	[30-39]	female	69
	9	[50-59]	female		9	[40-49]	male	96
	10	[50-59]	female		10	[18-29]	female	65

448 **Table S3: Primers used to assess the expression of listed genes.** Gene name, PubMed Nucleotide accession number used
449 for primer design, forward and reverse primer sequences and the size of the PCR product (in bp) 4 are given. All
450 primers were designed so that the PCR product span at least one exon-exon junction.
451

Gene	Forward primer	Reverse primer	Product size (bp)
SLC25(A5)	GTTGTCGCAGGTGGACTTCT	CCTTACCCTCACAACTGGC	71
GPAT1	CTGCTAGGGCAGCAGCG	TGCTGGGATGAAAGTTCTTCTGT	108
GPAT2	CTTCCCTTGAGCAGTCCACG	GCCATGAGAGCCTCACACCA	87
AGPAT1	ACAGAGACACAGCCATCCG	CAAATCCATTCTGGCCACCTCAG	102
LIPIN2	TCTCCGCCTTCCACAGAGAA	CTGCTTAGACGGGGCAAACA	98
DGAT1	CAACTACCGTGGCATCCTG	TTCTCCAGAAATAACCGGGC	72

452

453

454 **Table S4: Characteristics of the hPASM C and hPAEC donors used for in vitro studies.**

	ID	Age	Sex		ID	Age	Sex
hPASM C	1	[30-39]	male	hPAEC	1	[50-59]	male
	2	[50-59]	female		2	[40-49]	female
	3	[30-39]	male		3	[50-59]	female
	4	[30-39]	female		4	[50-59]	male
	5	[18-29]	female				
	6	[30-39]	male				

455